Identification	O
of	O
human	B-protein
leukemic	I-protein
glucocorticoid	I-protein
receptors	I-protein
using	O
affinity	O
labeling	O
and	O
anti-human	B-protein
glucocorticoid	I-protein
receptor	I-protein
antibodies	I-protein
.	O

Antisera	O
raised	O
against	O
human	B-protein
lymphoid	I-protein
glucocorticoid	I-protein
receptors	I-protein
were	O
used	O
in	O
combination	O
with	O
the	O
glucocorticoid	O
receptor	O
affinity	O
label	O
[	O
3H	O
]	O
dexamethasone	O
21-mesylate	O
[	O
(	O
3H	O
]	O
DM	O
)	O
to	O
identify	O
the	O
glucocorticoid	B-protein
receptors	I-protein
of	O
the	O
human	B-cell_line
B-lymphoblastoid	I-cell_line
cell	I-cell_line
line	I-cell_line
IM-9	B-cell_line
and	O
the	O
human	B-cell_line
T-cell	I-cell_line
leukemic	I-cell_line
cell	I-cell_line
line	I-cell_line
CEM-C7	B-cell_line
.	O

Antisera	O
were	O
obtained	O
following	O
immunization	O
of	O
New	O
Zealand	O
White	O
rabbits	O
with	O
[	B-protein
3H	I-protein
]	I-protein
triamcinolone	I-protein
acetonide	I-protein
[	I-protein
(	I-protein
3H	I-protein
]	I-protein
TA	I-protein
)	I-protein
-glucocorticoid	I-protein
receptor	I-protein
complexes	I-protein
partially	O
purified	O
by	O
two-stage	O
DNA-cellulose	O
chromatography	O
.	O

The	O
presence	O
of	O
anti-human	B-protein
glucocorticoid	I-protein
receptor	I-protein
antibodies	I-protein
was	O
verified	O
by	O
:	O
(	O
a	O
)	O
adsorption	O
of	O
[	B-protein
3H	I-protein
]	I-protein
TA-receptor-antibody	I-protein
complexes	I-protein
to	O
Protein	B-protein
A	I-protein
;	O
(	O
b	O
)	O
a	O
shift	O
to	O
higher	O
apparent	O
molecular	O
weight	O
in	O
the	O
elution	O
position	O
from	O
Sephacryl	O
S300	O
of	O
[	B-protein
3H	I-protein
]	I-protein
TA-receptor	I-protein
complexes	I-protein
incubated	O
with	O
immune	O
serum	O
;	O
and	O
(	O
c	O
)	O
the	O
ability	O
of	O
immune	O
serum	O
to	O
displace	O
[	B-protein
3H	I-protein
]	I-protein
TA-receptor	I-protein
complexes	I-protein
on	O
sucrose	O
gradients	O
.	O

These	O
antibodies	B-protein
also	O
recognized	O
rat	O
liver	O
and	O
murine	B-protein
S49	I-protein
cell	I-protein
glucocorticoid	I-protein
receptors	I-protein
.	O

Sodium	O
dodecyl	O
sulfate-polyacrylamide	O
gel	O
electrophoresis	O
of	O
[	O
3H	O
]	O
DM-labeled	O
IM-9	O
cytosol	O
identified	O
a	O
major	O
competable	O
band	O
with	O
a	O
molecular	O
weight	O
of	O
approximately	O
90	O
,	O
000	O
,	O
three	O
minor	O
competable	O
components	O
with	O
molecular	O
weights	O
of	O
approximately	O
78	O
,	O
000	O
,	O
approximately	O
51	O
,	O
000	O
,	O
and	O
approximately	O
38	O
,	O
500	O
,	O
and	O
at	O
least	O
21	O
other	O
noncompetable	O
components	O
.	O

Following	O
immunoprecipitation	O
of	O
[	O
3H	O
]	O
DM-labeled	O
cytosol	O
with	O
immune	O
serum	O
,	O
only	O
the	O
Mr	O
90	O
,	O
000	O
and	O
78	O
,	O
000	O
components	O
were	O
seen	O
.	O

Sodium	O
dodecyl	O
sulfate-polyacrylamide	O
gel	O
electrophoresis	O
of	O
[	O
3H	O
]	O
DM-labeled	O
CEM-C7	O
cytosol	O
revealed	O
a	O
larger	O
number	O
of	O
[	O
3H	O
]	O
DM-labeled	O
components	O
.	O

However	O
,	O
after	O
immunoprecipitation	O
of	O
[	O
3H	O
]	O
DM-labeled	O
CEM-C7	O
cytosol	O
,	O
a	O
predominant	O
competable	O
component	O
with	O
a	O
molecular	O
weight	O
of	O
90	O
,	O
000	O
was	O
easily	O
identified	O
.	O

This	O
component	O
was	O
markedly	O
diminished	O
when	O
cytosols	O
from	O
the	O
glucocorticoid	B-cell_line
receptor-deficient	I-cell_line
cell	I-cell_line
line	I-cell_line
ICR-27	B-cell_line
were	O
used	O
.	O

Thus	O
,	O
the	O
combination	O
of	O
affinity	O
labeling	O
and	O
anti-human	B-protein
glucocorticoid	I-protein
receptor	I-protein
antibodies	I-protein
is	O
capable	O
of	O
providing	O
direct	O
physical	O
identification	O
of	O
human	B-protein
lymphoid	I-protein
glucocorticoid	I-protein
receptors	I-protein
.	O

[	NULL
CANCER	NULL
RESEARCH	NULL
44	NULL
,	NULL
4540-4547	NULL
,	NULL
October	NULL
1984	NULL
]	NULL
Identification	NULL
of	NULL
Human	NULL
Leukemic	NULL
Glucocorticoid	NULL
Receptors	NULL
Using	NULL
Affinity	NULL
Labeling	NULL
and	NULL
Anti-Human	NULL
Glucocorticoid	NULL
Receptor	NULL
Antibodies	NULL
Jeffrey	NULL
M.	NULL
Harmon	NULL
,	NULL
``	NULL
Howard	NULL
J.	NULL
Eisen	NULL
,	NULL
Steven	NULL
T.	NULL
Brower	NULL
,	NULL
S.	NULL
Stoney	NULL
Simons	NULL
,	NULL
Jr.	NULL
,	NULL
Carol	NULL
L.	NULL
Langley	NULL
,	NULL
``	NULL
and	NULL
E.	NULL
Brad	NULL
Thompson	NULL
Department	NULL
of	NULL
Pharmacology	NULL
,	NULL
Uniformed	NULL
Services	NULL
University	NULL
of	NULL
the	NULL
Health	NULL
Sciences	NULL
,	NULL
Bethesda	NULL
,	NULL
Maryland	NULL
20814	NULL
[	NULL
J.	NULL
M.	NULL
H.	NULL
]	NULL
;	NULL
Laboratory	NULL
of	NULL
Biochemistry	NULL
,	NULL
Division	NULL
of	NULL
Cancer	NULL
Institute	NULL
of	NULL
Child	NULL
Health	NULL
and	NULL
Human	NULL
Dev	NULL
Digestive	NULL
and	NULL
Kidney	NULL
Diseases	NULL
,	NULL
Bethesda	NULL
,	NULL
Maryland	NULL
20205	NULL
[	NULL
S.	NULL
S.	NULL
S.	NULL
]	NULL
ABSTRACT	NULL
Antisera	NULL
raised	NULL
against	NULL
human	NULL
lymphoid	NULL
glucocorticoid	NULL
receptors	NULL
were	NULL
used	NULL
in	NULL
combination	NULL
with	NULL
the	NULL
glucocorticoid	NULL
receptor	NULL
affinity	NULL
label	NULL
[	NULL
°H	NULL
]	NULL
dexamethasone	NULL
21-mesylate	NULL
(	NULL
[	NULL
°HJDM	NULL
)	NULL
to	NULL
identify	NULL
the	NULL
glucocorticoid	NULL
receptors	NULL
of	NULL
the	NULL
human	NULL
B-lymphoblastoid	NULL
cell	NULL
line	NULL
IM-9	NULL
and	NULL
the	NULL
human	NULL
T-cell	NULL
leukemic	NULL
cell	NULL
line	NULL
CEM-C7	NULL
.	NULL

Antisera	NULL
were	NULL
obtained	NULL
following	NULL
immunization	NULL
of	NULL
New	NULL
Zealand	NULL
White	NULL
rabbits	NULL
with	NULL
[	NULL
°HJtriamcinolone	NULL
acetonide	NULL
(	NULL
[	NULL
°H	NULL
]	NULL
JTA	NULL
)	NULL
-gluco-corticoid	NULL
receptor	NULL
complexes	NULL
partially	NULL
purified	NULL
by	NULL
two-stage	NULL
DNA-cellulose	NULL
chromatography	NULL
.	NULL

The	NULL
presence	NULL
of	NULL
anti-human	NULL
glucocorticoid	NULL
receptor	NULL
antibodies	NULL
was	NULL
verified	NULL
by	NULL
:	NULL
(	NULL
a	NULL
)	NULL
adsorption	NULL
of	NULL
[	NULL
°H	NULL
]	NULL
TA-receptor-antibody	NULL
complexes	NULL
to	NULL
Protein	NULL
A	NULL
;	NULL
(	NULL
b	NULL
)	NULL
a	NULL
shift	NULL
to	NULL
higher	NULL
apparent	NULL
molecular	NULL
weight	NULL
in	NULL
the	NULL
elution	NULL
position	NULL
from	NULL
Sephacryl	NULL
$	NULL
300	NULL
of	NULL
[	NULL
°H	NULL
]	NULL
JTA-receptor	NULL
complexes	NULL
incubated	NULL
with	NULL
immune	NULL
serum	NULL
;	NULL
and	NULL
(	NULL
c	NULL
)	NULL
the	NULL
ability	NULL
of	NULL
immune	NULL
serum	NULL
to	NULL
displace	NULL
[	NULL
PH	NULL
]	NULL
JTA-receptor	NULL
complexes	NULL
on	NULL
sucrose	NULL
gradients	NULL
.	NULL

These	NULL
antibodies	NULL
also	NULL
recognized	NULL
rat	NULL
liver	NULL
and	NULL
murine	NULL
$	NULL
49	NULL
cell	NULL
glucocorticoid	NULL
receptors	NULL
.	NULL

Sodium	NULL
dodecyl	NULL
sulfate-polyacrylamide	NULL
gel	NULL
electrophoresis	NULL
of	NULL
[	NULL
°HJDM-labeled	NULL
IM-9	NULL
cytosol	NULL
identified	NULL
a	NULL
major	NULL
competable	NULL
band	NULL
with	NULL
a	NULL
molecular	NULL
weight	NULL
of	NULL
~90,000	NULL
,	NULL
three	NULL
minor	NULL
competable	NULL
components	NULL
with	NULL
molecular	NULL
weights	NULL
of	NULL
~78,000	NULL
,	NULL
~51,000	NULL
,	NULL
and	NULL
~38,500	NULL
,	NULL
and	NULL
at	NULL
least	NULL
21	NULL
other	NULL
noncom-petable	NULL
components	NULL
.	NULL

Following	NULL
immunoprecipitation	NULL
of	NULL
[	NULL
°HJDM-labeled	NULL
cytosol	NULL
with	NULL
immune	NULL
serum	NULL
,	NULL
only	NULL
the	NULL
M	NULL
,	NULL
90,000	NULL
and	NULL
78,000	NULL
components	NULL
were	NULL
seen	NULL
.	NULL

Sodium	NULL
dodecyl	NULL
sulfate-polyacrylamide	NULL
gel	NULL
electrophoresis	NULL
of	NULL
[	NULL
°HJDM-labeled	NULL
CEM-C7	NULL
cytosol	NULL
revealed	NULL
a	NULL
larger	NULL
number	NULL
of	NULL
[	NULL
°HJDM-labeled	NULL
components	NULL
.	NULL

However	NULL
,	NULL
after	NULL
immunoprecipitation	NULL
of	NULL
[	NULL
°HJDM-labeled	NULL
CEM-C7	NULL
cytosol	NULL
,	NULL
a	NULL
predominant	NULL
competable	NULL
component	NULL
with	NULL
a	NULL
molecular	NULL
weight	NULL
of	NULL
90,000	NULL
was	NULL
easily	NULL
identified	NULL
.	NULL

This	NULL
component	NULL
was	NULL
markedly	NULL
diminished	NULL
when	NULL
cytosols	NULL
from	NULL
the	NULL
glucocorticoid	NULL
receptor-deficient	NULL
cell	NULL
line	NULL
ICR-27	NULL
were	NULL
used	NULL
.	NULL

Thus	NULL
,	NULL
the	NULL
combination	NULL
of	NULL
affinity	NULL
labeling	NULL
and	NULL
anti-human	NULL
glucocorticoid	NULL
receptor	NULL
antibodies	NULL
is	NULL
capable	NULL
of	NULL
providing	NULL
direct	NULL
physical	NULL
identification	NULL
of	NULL
human	NULL
lymphoid	NULL
glucocorticoid	NULL
receptors	NULL
.	NULL

INTRODUCTION	NULL
The	NULL
lympholytic	NULL
activity	NULL
of	NULL
glucocorticoids	NULL
has	NULL
resulted	NULL
in	NULL
their	NULL
incorporation	NULL
into	NULL
multidrug	NULL
chemotherapeutic	NULL
regimens	NULL
for	NULL
the	NULL
treatment	NULL
of	NULL
various	NULL
leukemias	NULL
and	NULL
lymphomas	NULL
.	NULL

This	NULL
has	NULL
stim-	NULL
*	NULL
Supported	NULL
in	NULL
part	NULL
by	NULL
Grant	NULL
CA	NULL
32226	NULL
from	NULL
the	NULL
National	NULL
Cancer	NULL
Institute	NULL
to	NULL
J.	NULL
M.	NULL
Harmon	NULL
.	NULL

*	NULL
To	NULL
whom	NULL
requests	NULL
for	NULL
reprints	NULL
should	NULL
be	NULL
addressed	NULL
.	NULL

®	NULL
Present	NULL
address	NULL
:	NULL
Dartmouth	NULL
Medical	NULL
School	NULL
,	NULL
Hanover	NULL
,	NULL
NH	NULL
03755	NULL
.	NULL

Received	NULL
January	NULL
30	NULL
,	NULL
1984	NULL
;	NULL
accepted	NULL
June	NULL
21	NULL
,	NULL
1984	NULL
.	NULL

4540	NULL
and	NULL
Diagnosis	NULL
,	NULL
National	NULL
Cancer	NULL
Institute	NULL
,	NULL
Bethesda	NULL
,	NULL
Maryland	NULL
20205	NULL
[	NULL
S.	NULL
T.	NULL
B.	NULL
,	NULL
C.	NULL
L.	NULL
L.	NULL
,	NULL
E.	NULL
B.	NULL
T.	NULL
]	NULL
;	NULL
Laboratory	NULL
of	NULL
Developmental	NULL
Phi	NULL
,	NULL
National	NULL
,	NULL
Bethesda	NULL
,	NULL
Maryland	NULL
20205	NULL
[	NULL
H.	NULL
J.	NULL
E.	NULL
]	NULL
;	NULL
and	NULL
Laboratory	NULL
of	NULL
Chemistry	NULL
,	NULL
National	NULL
Institute	NULL
of	NULL
Arthritis	NULL
,	NULL
Diabetes	NULL
,	NULL
and	NULL
ulated	NULL
the	NULL
study	NULL
of	NULL
glucocorticoid	NULL
receptors	NULL
in	NULL
normal	NULL
and	NULL
leukemic	NULL
cells	NULL
in	NULL
order	NULL
to	NULL
determine	NULL
if	NULL
receptor	NULL
concentration	NULL
or	NULL
status	NULL
can	NULL
be	NULL
used	NULL
to	NULL
predict	NULL
clinical	NULL
response	NULL
(	NULL
1	NULL
,	NULL
17	NULL
,	NULL
19	NULL
,	NULL
21	NULL
,	NULL
24	NULL
,	NULL
25	NULL
)	NULL
.	NULL

While	NULL
several	NULL
studies	NULL
have	NULL
suggested	NULL
that	NULL
a	NULL
positive	NULL
correlation	NULL
exists	NULL
between	NULL
glucocorticoid	NULL
receptor	NULL
concentration	NULL
and	NULL
clinical	NULL
response	NULL
,	NULL
it	NULL
is	NULL
clear	NULL
that	NULL
many	NULL
patients	NULL
with	NULL
high	NULL
levels	NULL
of	NULL
glucocorticoid	NULL
receptor	NULL
binding	NULL
activity	NULL
fail	NULL
to	NULL
respond	NULL
to	NULL
therapy	NULL
(	NULL
1	NULL
,	NULL
19	NULL
,	NULL
21	NULL
,	NULL
24	NULL
)	NULL
.	NULL

in	NULL
theory	NULL
,	NULL
this	NULL
could	NULL
result	NULL
from	NULL
the	NULL
fact	NULL
that	NULL
glucocorticoid	NULL
receptor	NULL
binding	NULL
activity	NULL
is	NULL
a	NULL
necessary	NULL
but	NULL
insufficient	NULL
marker	NULL
for	NULL
glucocorticoid	NULL
response	NULL
.	NULL

Indeed	NULL
,	NULL
we	NULL
have	NULL
described	NULL
previously	NULL
mutants	NULL
derived	NULL
from	NULL
the	NULL
glucocorticoid-sensitive	NULL
human	NULL
leukemic	NULL
cell	NULL
line	NULL
CEM-C7	NULL
which	NULL
exhibit	NULL
considerable	NULL
amounts	NULL
of	NULL
glucocorticoid	NULL
receptor	NULL
binding	NULL
activity	NULL
but	NULL
which	NULL
are	NULL
completely	NULL
unresponsive	NULL
to	NULL
glucocorticoids	NULL
(	NULL
15	NULL
,	NULL
16	NULL
)	NULL
.	NULL

Detailed	NULL
biochemical	NULL
analyses	NULL
of	NULL
these	NULL
mutants	NULL
revealed	NULL
subtle	NULL
defects	NULL
in	NULL
their	NULL
glucocorticoid	NULL
receptors	NULL
,	NULL
principally	NULL
in	NULL
their	NULL
ability	NULL
to	NULL
form	NULL
and	NULL
maintain	NULL
the	NULL
activated	NULL
state	NULL
of	NULL
the	NULL
SR*	NULL
complex	NULL
essential	NULL
for	NULL
biological	NULL
response	NULL
(	NULL
15	NULL
,	NULL
33	NULL
)	NULL
.	NULL

While	NULL
detailed	NULL
biochemical	NULL
analysis	NULL
of	NULL
receptors	NULL
is	NULL
possible	NULL
on	NULL
a	NULL
small	NULL
number	NULL
of	NULL
samples	NULL
of	NULL
sufficient	NULL
size	NULL
,	NULL
such	NULL
analyses	NULL
are	NULL
extremely	NULL
difficult	NULL
to	NULL
perform	NULL
on	NULL
a	NULL
large	NULL
number	NULL
of	NULL
samples	NULL
.	NULL

Recently	NULL
,	NULL
a	NULL
number	NULL
of	NULL
laboratories	NULL
have	NULL
succeeded	NULL
in	NULL
the	NULL
preparation	NULL
of	NULL
antisera	NULL
or	NULL
monoclonal	NULL
antibodies	NULL
against	NULL
several	NULL
steroid	NULL
hormone	NULL
receptors	NULL
,	NULL
including	NULL
human	NULL
estrophilin	NULL
and	NULL
the	NULL
rat	NULL
liver	NULL
glucocorticoid	NULL
receptor	NULL
(	NULL
6	NULL
,	NULL
10-14	NULL
,	NULL
22	NULL
,	NULL
27	NULL
,	NULL
30	NULL
,	NULL
31	NULL
,	NULL
43	NULL
)	NULL
.	NULL

These	NULL
reagents	NULL
provide	NULL
powerful	NULL
new	NULL
tools	NULL
for	NULL
the	NULL
analysis	NULL
of	NULL
steroid	NULL
hormone	NULL
receptors	NULL
.	NULL

However	NULL
,	NULL
the	NULL
requirement	NULL
for	NULL
retention	NULL
of	NULL
a	NULL
reversibly	NULL
bound	NULL
radioactive	NULL
ligand	NULL
and	NULL
the	NULL
weak	NULL
cross-reactivity	NULL
between	NULL
anti-rat	NULL
liver	NULL
glucocorticoid	NULL
receptor	NULL
antibodies	NULL
and	NULL
human	NULL
glucocorticoid	NULL
receptors	NULL
(	NULL
Footnote	NULL
5	NULL
;	NULL
Ref	NULL
.	NULL

40	NULL
)	NULL
have	NULL
limited	NULL
the	NULL
use	NULL
of	NULL
anti-rat	NULL
liver	NULL
glucocorticoid	NULL
receptor	NULL
antibodies	NULL
for	NULL
the	NULL
study	NULL
of	NULL
human	NULL
glucocorticoid	NULL
receptors	NULL
.	NULL

We	NULL
have	NULL
described	NULL
previously	NULL
(	NULL
8	NULL
,	NULL
39	NULL
)	NULL
the	NULL
properties	NULL
of	NULL
an	NULL
electrophilic	NULL
affinity	NULL
ligand	NULL
for	NULL
the	NULL
glucocorticoid	NULL
receptor	NULL
,	NULL
[	NULL
°H	NULL
]	NULL
-DM	NULL
,	NULL
which	NULL
forms	NULL
a	NULL
covalent	NULL
complex	NULL
with	NULL
the	NULL
glucocorticoid	NULL
receptor	NULL
.	NULL

Although	NULL
this	NULL
reagent	NULL
is	NULL
not	NULL
entirely	NULL
specific	NULL
for	NULL
the	NULL
glucocorticoid	NULL
receptor	NULL
,	NULL
it	NULL
has	NULL
been	NULL
used	NULL
in	NULL
conjunction	NULL
with	NULL
anti-rat	NULL
liver	NULL
glucocorticoid	NULL
receptor	NULL
antibodies	NULL
to	NULL
identify	NULL
a	NULL
single	NULL
M.	NULL
90,000	NULL
component	NULL
from	NULL
partially	NULL
purified	NULL
rat	NULL
liver	NULL
cytosolic	NULL
proteins	NULL
,	NULL
which	NULL
appears	NULL
to	NULL
be	NULL
the	NULL
rat	NULL
liver	NULL
glucocorticoid	NULL
receptor	NULL
(	NULL
8	NULL
,	NULL
38	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
this	NULL
reagent	NULL
eliminates	NULL
the	NULL
requirement	NULL
for	NULL
retention	NULL
*	NULL
The	NULL
abbreviations	NULL
used	NULL
are	NULL
:	NULL
SR	NULL
,	NULL
steroid-receptor	NULL
;	NULL
DM	NULL
,	NULL
dexamethasone	NULL
21-mesylate	NULL
;	NULL
TA	NULL
,	NULL
triamcinolone	NULL
acetonide	NULL
;	NULL
SDS	NULL
,	NULL
sodium	NULL
dodecyl	NULL
sulfate	NULL
;	NULL
PAGE	NULL
,	NULL
poly-acrylamide	NULL
gel	NULL
electrophoresis	NULL
;	NULL
HTC	NULL
,	NULL
hepatoma	NULL
tissue	NULL
culture	NULL
;	NULL
HENDG	NULL
,	NULL
10	NULL
mm	NULL
4-	NULL
(	NULL
2-hydroxyethy	NULL
(	NULL
)	NULL
-1-piperazineethanesulfonic	NULL
acid-1	NULL
mm	NULL
EDTA-100	NULL
mm	NULL
NaCt+-O0.5	NULL
mm	NULL
dithiothreitol-10	NULL
%	NULL
glycerol	NULL
(	NULL
pH	NULL
7.6	NULL
)	NULL
.	NULL

®	NULL
J.	NULL
M.	NULL
Harmon	NULL
and	NULL
R.	NULL
W.	NULL
Harrison	NULL
,	NULL
unpublished	NULL
results	NULL
.	NULL

CANCER	NULL
RESEARCH	NULL
VOL	NULL
.	NULL

44	NULL
Downloaded	NULL
from	NULL
cancerres.aacrjournals.org	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

©	NULL
1984	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
.	NULL

of	NULL
a	NULL
reversibly	NULL
bound	NULL
ligand	NULL
in	NULL
order	NULL
to	NULL
identity	NULL
the	NULL
glucocorticoid	NULL
receptor	NULL
.	NULL

To	NULL
study	NULL
human	NULL
glucocorticoid	NULL
receptors	NULL
,	NULL
we	NULL
have	NULL
now	NULL
prepared	NULL
antisera	NULL
against	NULL
highly	NULL
purified	NULL
preparations	NULL
of	NULL
human	NULL
lymphoid	NULL
glucocorticoid	NULL
receptors	NULL
.	NULL

We	NULL
report	NULL
here	NULL
the	NULL
preparation	NULL
of	NULL
these	NULL
antisera	NULL
and	NULL
their	NULL
properties	NULL
.	NULL

Using	NULL
[	NULL
°HJDM	NULL
,	NULL
4	NULL
steroid-specific	NULL
binding	NULL
components	NULL
(	NULL
M	NULL
,	NULL
=90,000	NULL
,	NULL
78,000	NULL
,	NULL
51,000	NULL
,	NULL
and	NULL
38,500	NULL
)	NULL
were	NULL
identified	NULL
in	NULL
crude	NULL
cytosol	NULL
prepared	NULL
from	NULL
IM-9	NULL
lymphoblastoid	NULL
cells	NULL
.	NULL

Only	NULL
the	NULL
2	NULL
largest	NULL
of	NULL
these	NULL
components	NULL
reacted	NULL
with	NULL
anti-human	NULL
glucocorticoid	NULL
receptor	NULL
antibody	NULL
.	NULL

Similar	NULL
analysis	NULL
of	NULL
cytosol	NULL
prepared	NULL
from	NULL
the	NULL
human	NULL
T-cell	NULL
line	NULL
CEM-C7	NULL
also	NULL
identified	NULL
a	NULL
protein	NULL
of	NULL
M	NULL
,	NULL
290,000	NULL
.	NULL

The	NULL
concentration	NULL
of	NULL
this	NULL
protein	NULL
was	NULL
markedly	NULL
reduced	NULL
in	NULL
mutants	NULL
containing	NULL
diminished	NULL
quantities	NULL
of	NULL
glucocorticoid	NULL
receptor	NULL
binding	NULL
activity	NULL
.	NULL

These	NULL
results	NULL
suggest	NULL
that	NULL
we	NULL
have	NULL
prepared	NULL
antisera	NULL
specific	NULL
for	NULL
the	NULL
glucocorticoid	NULL
receptor	NULL
and	NULL
that	NULL
the	NULL
reduced	NULL
denatured	NULL
steroid	NULL
binding	NULL
component	NULL
of	NULL
the	NULL
human	NULL
glucocorticoid	NULL
receptor	NULL
is	NULL
a	NULL
protein	NULL
with	NULL
a	NULL
molecular	NULL
weight	NULL
of	NULL
approximately	NULL
90,000	NULL
.	NULL

MATERIALS	NULL
AND	NULL
METHODS	NULL
Cells	NULL
and	NULL
Cell	NULL
Culture	NULL
.	NULL

IM-9	NULL
cells	NULL
obtained	NULL
from	NULL
the	NULL
laboratory	NULL
of	NULL
Dr.	NULL
Jesse	NULL
Roth	NULL
(	NULL
Diabetes	NULL
Branch	NULL
,	NULL
National	NULL
Institute	NULL
of	NULL
Arthritis	NULL
,	NULL
Diabetes	NULL
,	NULL
and	NULL
Digestive	NULL
and	NULL
Kidney	NULL
Diseases	NULL
,	NULL
NIH	NULL
,	NULL
Bethesda	NULL
,	NULL
MD	NULL
)	NULL
were	NULL
grown	NULL
in	NULL
RPMI	NULL
1640	NULL
(	NULL
Biofluids	NULL
,	NULL
Rockville	NULL
,	NULL
MD	NULL
)	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
5	NULL
%	NULL
fetal	NULL
bovine	NULL
serum	NULL
(	NULL
KC	NULL
Biologicals	NULL
,	NULL
St.	NULL
Louis	NULL
,	NULL
MO	NULL
)	NULL
.	NULL

The	NULL
glucocorticoid-sensitive	NULL
human	NULL
leukemic	NULL
cell	NULL
line	NULL
,	NULL
CEM-C7	NULL
,	NULL
and	NULL
the	NULL
receptor-deficient	NULL
mutant	NULL
,	NULL
ICR-27	NULL
(	NULL
16	NULL
)	NULL
,	NULL
were	NULL
grown	NULL
in	NULL
RPMI	NULL
1640	NULL
medium	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
10	NULL
%	NULL
fetal	NULL
bovine	NULL
serum	NULL
.	NULL

The	NULL
murine	NULL
cell	NULL
line	NULL
$	NULL
49	NULL
was	NULL
obtained	NULL
from	NULL
Dr.	NULL
Gordon	NULL
Hager	NULL
(	NULL
Laboratory	NULL
of	NULL
Tumor	NULL
Virus	NULL
Genetics	NULL
,	NULL
National	NULL
Cancer	NULL
Institute	NULL
,	NULL
Bethesda	NULL
,	NULL
MD	NULL
)	NULL
and	NULL
grown	NULL
in	NULL
Dulbecco	NULL
's	NULL
modified	NULL
Eagle	NULL
's	NULL
medium	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
10	NULL
%	NULL
fetal	NULL
bovine	NULL
serum	NULL
.	NULL

All	NULL
cell	NULL
lines	NULL
were	NULL
grown	NULL
as	NULL
stationary	NULL
suspensions	NULL
in	NULL
a	NULL
humidified	NULL
atmosphere	NULL
of	NULL
95	NULL
%	NULL
air	NULL
and	NULL
5	NULL
%	NULL
CO	NULL
;	NULL
.	NULL

Cells	NULL
were	NULL
maintained	NULL
at	NULL
a	NULL
density	NULL
of	NULL
10°	NULL
to	NULL
2	NULL
x	NULL
10°	NULL
cells/	NULL
mi	NULL
.	NULL

Preparation	NULL
of	NULL
Cytosol	NULL
.	NULL

For	NULL
most	NULL
experiments	NULL
,	NULL
cells	NULL
were	NULL
harvested	NULL
by	NULL
centrifugation	NULL
(	NULL
800	NULL
x	NULL
g	NULL
)	NULL
and	NULL
washed	NULL
twice	NULL
in	NULL
Hanks	NULL
'	NULL
balanced	NULL
salts	NULL
solution	NULL
.	NULL

Unless	NULL
otherwise	NULL
indicated	NULL
,	NULL
all	NULL
further	NULL
work	NULL
was	NULL
performed	NULL
at	NULL
0-4°	NULL
.	NULL

The	NULL
final	NULL
cell	NULL
pellet	NULL
was	NULL
resuspended	NULL
in	NULL
an	NULL
equal	NULL
volume	NULL
of	NULL
homogenization	NULL
buffer	NULL
[	NULL
10	NULL
mm	NULL
4-	NULL
{	NULL
2-hydroxyethyl	NULL
)	NULL
-1-piperazineethane-sulfonic	NULL
acid-1	NULL
mm	NULL
EDTA-10	NULL
mm	NULL
NaCL-O0.5	NULL
mm	NULL
dithiothreitol	NULL
,	NULL
pH	NULL
7.6	NULL
)	NULL
and	NULL
immediately	NULL
homogenized	NULL
with	NULL
15	NULL
strokes	NULL
of	NULL
a	NULL
Ten	NULL
Broeck	NULL
ground	NULL
glass	NULL
homogenizer	NULL
.	NULL

Following	NULL
centrifugation	NULL
at	NULL
150,000	NULL
x	NULL
g	NULL
for	NULL
90	NULL
min	NULL
at	NULL
O-2°	NULL
,	NULL
the	NULL
supernatant	NULL
was	NULL
immediately	NULL
adjusted	NULL
to	NULL
contain	NULL
10	NULL
%	NULL
glycerol	NULL
and	NULL
0.1	NULL
m	NULL
NaCI	NULL
.	NULL

Cytosols	NULL
prepared	NULL
in	NULL
this	NULL
manner	NULL
were	NULL
either	NULL
used	NULL
immediately	NULL
or	NULL
quick	NULL
frozen	NULL
in	NULL
liquid	NULL
N	NULL
;	NULL
and	NULL
stored	NULL
in	NULL
liquid	NULL
N	NULL
;	NULL
.	NULL

Frozen	NULL
cytosols	NULL
contained	NULL
100	NULL
%	NULL
of	NULL
receptor	NULL
binding	NULL
activity	NULL
for	NULL
up	NULL
to	NULL
3	NULL
months	NULL
with	NULL
no	NULL
evidence	NULL
of	NULL
further	NULL
receptor	NULL
degradation	NULL
or	NULL
proteolysis	NULL
.	NULL

Purification	NULL
of	NULL
Glucocorticoid	NULL
Receptor	NULL
.	NULL

For	NULL
each	NULL
experiment	NULL
,	NULL
cytosol	NULL
was	NULL
prepared	NULL
from	NULL
2	NULL
x	NULL
10	NULL
``	NULL
IM-9	NULL
cells	NULL
as	NULL
described	NULL
above	NULL
.	NULL

Cytosol	NULL
was	NULL
labeled	NULL
for	NULL
2	NULL
hr	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
100	NULL
nm	NULL
[	NULL
°H	NULL
]	NULL
JTA	NULL
(	NULL
Amersham	NULL
,	NULL
Arlington	NULL
Heights	NULL
,	NULL
IL	NULL
20	NULL
Ci/mmof	NULL
)	NULL
,	NULL
and	NULL
[	NULL
°HJTA-receptor	NULL
complexes	NULL
were	NULL
purified	NULL
with	NULL
minor	NULL
modifications	NULL
by	NULL
the	NULL
2-stage	NULL
DNA-cellulose	NULL
chromat-ographic	NULL
procedure	NULL
of	NULL
Eisen	NULL
and	NULL
Glinsmann	NULL
(	NULL
7	NULL
)	NULL
.	NULL

All	NULL
chromatography	NULL
was	NULL
performed	NULL
in	NULL
HENDG	NULL
buffer	NULL
.	NULL

The	NULL
second	NULL
DNA-cellulose	NULL
column	NULL
was	NULL
eluted	NULL
with	NULL
HENDG	NULL
buffer	NULL
containing	NULL
10	NULL
mm	NULL
pyridoxal	NULL
phosphate	NULL
.	NULL

Purified	NULL
receptor	NULL
was	NULL
concentrated	NULL
by	NULL
adsorption	NULL
to	NULL
hydroxylapatite	NULL
and	NULL
eluted	NULL
with	NULL
0.4	NULL
m	NULL
phosphate	NULL
buffer	NULL
,	NULL
pH	NULL
7.2.	NULL
immunization	NULL
of	NULL
Rabbits	NULL
.	NULL

Female	NULL
New	NULL
Zealand	NULL
White	NULL
rabbits	NULL
were	NULL
immunized	NULL
at	NULL
4-week	NULL
intervals	NULL
with	NULL
50	NULL
to	NULL
80	NULL
pmol	NULL
of	NULL
purified	NULL
receptor	NULL
at	NULL
multiple	NULL
dorsal	NULL
intradermal	NULL
sites	NULL
.	NULL

The	NULL
first	NULL
2	NULL
immunizations	NULL
of	NULL
each	NULL
rabbit	NULL
were	NULL
performed	NULL
in	NULL
complete	NULL
Freund	NULL
's	NULL
adjuvant	NULL
(	NULL
Grand	NULL
Island	NULL
Biological	NULL
Co.	NULL
,	NULL
Grand	NULL
Island	NULL
,	NULL
NY	NULL
)	NULL
.	NULL

Subsequent	NULL
immunizations	NULL
were	NULL
performed	NULL
in	NULL
OCTOBER	NULL
1984	NULL
Anti-Human	NULL
Glucocorticoid	NULL
Receptor	NULL
Antibodies	NULL
incomplete	NULL
adjuvant	NULL
.	NULL

Ten	NULL
days	NULL
after	NULL
each	NULL
immunization	NULL
,	NULL
serum	NULL
was	NULL
collected	NULL
and	NULL
assayed	NULL
for	NULL
antibody	NULL
activity	NULL
.	NULL

Determination	NULL
of	NULL
antibody	NULL
activity	NULL
was	NULL
performed	NULL
by	NULL
incubating	NULL
crude	NULL
[	NULL
°H	NULL
]	NULL
JTA-labeled	NULL
cytosols	NULL
with	NULL
various	NULL
dilutions	NULL
of	NULL
serum	NULL
,	NULL
followed	NULL
by	NULL
adsorption	NULL
of	NULL
[	NULL
°HJTA-receptor-antibody	NULL
complexes	NULL
to	NULL
formalin	NULL
fixed	NULL
Staphylococcus	NULL
aureus	NULL
membranes	NULL
(	NULL
18	NULL
)	NULL
.	NULL

Conjugates	NULL
were	NULL
pelleted	NULL
by	NULL
centrifugation	NULL
at	NULL
12,000	NULL
x	NULL
g	NULL
and	NULL
washed	NULL
twice	NULL
in	NULL
HENDG	NULL
buffer	NULL
containing	NULL
20	NULL
mm	NULL
sodium	NULL
molybdate	NULL
.	NULL

The	NULL
final	NULL
pellets	NULL
were	NULL
resuspended	NULL
in	NULL
1.0	NULL
ml	NULL
of	NULL
HENDG	NULL
buffer	NULL
and	NULL
counted	NULL
by	NULL
liquid	NULL
scintillation	NULL
methods	NULL
using	NULL
a	NULL
Beckman	NULL
LS-7800	NULL
liquid	NULL
scintillation	NULL
spectrometer	NULL
programmed	NULL
for	NULL
dpm	NULL
conversion	NULL
.	NULL

Gel	NULL
Filtration	NULL
.	NULL

[	NULL
°H	NULL
]	NULL
TA-labeled	NULL
samples	NULL
(	NULL
0.3	NULL
mi	NULL
)	NULL
were	NULL
applied	NULL
to	NULL
a	NULL
1-	NULL
x	NULL
40-cm	NULL
(	NULL
38	NULL
mi	NULL
)	NULL
column	NULL
of	NULL
Sephacryl	NULL
$	NULL
300	NULL
(	NULL
Pharmacia	NULL
Fine	NULL
Chemicals	NULL
,	NULL
Piscataway	NULL
,	NULL
NJ	NULL
)	NULL
equilibrated	NULL
with	NULL
HENDG	NULL
buffer	NULL
containing	NULL
0.5	NULL
m	NULL
NaCl	NULL
.	NULL

Chromatography	NULL
was	NULL
performed	NULL
at	NULL
a	NULL
flow	NULL
rate	NULL
of	NULL
11	NULL
mi/hr	NULL
,	NULL
and	NULL
1.0-ml	NULL
fractions	NULL
were	NULL
collected	NULL
and	NULL
assayed	NULL
for	NULL
radioactivity	NULL
.	NULL

The	NULL
apparent	NULL
Stokes	NULL
'	NULL
radius	NULL
of	NULL
eluted	NULL
SR	NULL
complexes	NULL
was	NULL
computed	NULL
from	NULL
standard	NULL
curves	NULL
of	NULL
(	NULL
-log	NULL
K	NULL
,	NULL
,	NULL
)	NULL
*	NULL
versus	NULL
Stokes	NULL
'	NULL
radii	NULL
obtained	NULL
for	NULL
the	NULL
protein	NULL
standards	NULL
thyroglobulin	NULL
(	NULL
R	NULL
,	NULL
=	NULL
8.5	NULL
nm	NULL
)	NULL
,	NULL
ferritin	NULL
(	NULL
R	NULL
,	NULL
=	NULL
6.1	NULL
nm	NULL
)	NULL
,	NULL
catalase	NULL
(	NULL
R	NULL
,	NULL
=	NULL
5.2	NULL
nm	NULL
)	NULL
,	NULL
aldolase	NULL
(	NULL
A	NULL
,	NULL
=	NULL
4.8	NULL
nm	NULL
)	NULL
,	NULL
bovine	NULL
serum	NULL
albumin	NULL
(	NULL
A	NULL
,	NULL
=	NULL
3.6	NULL
nm	NULL
)	NULL
,	NULL
and	NULL
ovalbumin	NULL
(	NULL
R	NULL
,	NULL
=	NULL
3.1	NULL
nm	NULL
)	NULL
(	NULL
Pharmacia	NULL
Fine	NULL
Chemicals	NULL
,	NULL
Piscataway	NULL
,	NULL
NJ	NULL
)	NULL
.	NULL

Samples	NULL
routinely	NULL
contained	NULL
'*C-bovine	NULL
serum	NULL
albumin	NULL
as	NULL
an	NULL
internal	NULL
standard	NULL
.	NULL

Sucrose	NULL
Gradient	NULL
Centrifugation	NULL
.	NULL

Samples	NULL
(	NULL
200	NULL
L1	NULL
)	NULL
were	NULL
layered	NULL
onto	NULL
4.8-ml	NULL
5	NULL
to	NULL
20	NULL
%	NULL
linear	NULL
sucrose	NULL
gradients	NULL
in	NULL
buffer	NULL
(	NULL
10	NULL
mm	NULL
4-	NULL
(	NULL
2-hydroxyethy	NULL
!	NULL
)	NULL

-1-piperazineethanesulfonic	NULL
acid-1	NULL
mm	NULL
EDTA-0.5	NULL
mm	NULL
dithiothreitol	NULL
,	NULL
pH	NULL
7.6	NULL
)	NULL
containing	NULL
0.5	NULL
m	NULL
NaCI	NULL
.	NULL

Gradients	NULL
were	NULL
subjected	NULL
to	NULL
centrifugation	NULL
in	NULL
a	NULL
Beckman	NULL
SW50.1	NULL
rotor	NULL
at	NULL
200,000	NULL
x	NULL
g	NULL
for	NULL
18	NULL
hr	NULL
at	NULL
4°	NULL
and	NULL
then	NULL
fractionated	NULL
into	NULL
0.2-ml	NULL
fractions	NULL
using	NULL
a	NULL
Buchler	NULL
Auto	NULL
Densi-Flow	NULL
IIC	NULL
gradient	NULL
fractionater	NULL
.	NULL

All	NULL
gradients	NULL
contained	NULL
'	NULL
``	NULL
C-bovine	NULL
serum	NULL
albumin	NULL
as	NULL
an	NULL
internal	NULL
standard	NULL
.	NULL

Approximate	NULL
sedimentation	NULL
coefficients	NULL
were	NULL
determined	NULL
as	NULL
described	NULL
by	NULL
Martin	NULL
and	NULL
Ames	NULL
(	NULL
23	NULL
)	NULL
.	NULL

Affinity	NULL
Labeling	NULL
of	NULL
Glucocorticoid	NULL
Receptor	NULL
.	NULL

Crude	NULL
cytosol	NULL
(	NULL
50	NULL
ul	NULL
)	NULL
prepared	NULL
without	NULL
dithiothreitol	NULL
was	NULL
incubated	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
200	NULL
nm	NULL
HJDM	NULL
(	NULL
37	NULL
)	NULL
for	NULL
4	NULL
hr	NULL
at	NULL
0-4°	NULL
.	NULL

Samples	NULL
were	NULL
either	NULL
diluted	NULL
with	NULL
an	NULL
equal	NULL
volume	NULL
of	NULL
sample	NULL
buffer	NULL
(	NULL
0.125	NULL
m	NULL
Tris-HCH-4	NULL
%	NULL
SDS-20	NULL
%	NULL
glycerol-10	NULL
%	NULL
B-mercaptoethanol	NULL
,	NULL
pH	NULL
6.8	NULL
)	NULL
or	NULL
incubated	NULL
with	NULL
10	NULL
L1	NULL
of	NULL
immune	NULL
or	NULL
nonimmune	NULL
serum	NULL
for	NULL
4	NULL
hr	NULL
at	NULL
0-4°	NULL
.	NULL

Samples	NULL
incubated	NULL
with	NULL
antibody	NULL
were	NULL
adsorbed	NULL
to	NULL
Sepharose	NULL
CL-4B-immobilized	NULL
Protein	NULL
A	NULL
(	NULL
Pharmacia	NULL
Fine	NULL
Chemicals	NULL
)	NULL
for	NULL
30	NULL
min	NULL
followed	NULL
by	NULL
centrifugation	NULL
at	NULL
1500	NULL
x	NULL
g	NULL
for	NULL
1	NULL
min	NULL
.	NULL

The	NULL
resulting	NULL
pellets	NULL
were	NULL
washed	NULL
3	NULL
times	NULL
with	NULL
1.0	NULL
ml	NULL
of	NULL
HENDG	NULL
buffer	NULL
,	NULL
followed	NULL
by	NULL
elution	NULL
of	NULL
[	NULL
°HJDM	NULL
receptor	NULL
complexes	NULL
with	NULL
electrophoresis	NULL
sample	NULL
buffer	NULL
(	NULL
20	NULL
)	NULL
.	NULL

SDS-PAGE	NULL
.	NULL

SDS-PAGE	NULL
was	NULL
performed	NULL
as	NULL
described	NULL
by	NULL
Laemmii	NULL
(	NULL
20	NULL
)	NULL
.	NULL

Following	NULL
electrophoresis	NULL
,	NULL
gels	NULL
were	NULL
fixed	NULL
in	NULL
10	NULL
%	NULL
acetic	NULL
acid	NULL
and	NULL
then	NULL
impregnated	NULL
with	NULL
EN°HANCE	NULL
(	NULL
New	NULL
England	NULL
Nuclear	NULL
,	NULL
Boston	NULL
,	NULL
MA	NULL
}	NULL
.	NULL

Impregnated	NULL
gels	NULL
were	NULL
dried	NULL
,	NULL
and	NULL
the	NULL
radioactivity	NULL
was	NULL
visualized	NULL
by	NULL
fluorography	NULL
at	NULL
-70°	NULL
using	NULL
Kodak	NULL
XAR-5	NULL
film	NULL
(	NULL
Eastman	NULL
Kodak	NULL
,	NULL
Roch-ester	NULL
,	NULL
NY	NULL
)	NULL
.	NULL

Molecular	NULL
weights	NULL
were	NULL
determined	NULL
from	NULL
standard	NULL
curves	NULL
constructed	NULL
from	NULL
the	NULL
mobilities	NULL
of	NULL
the	NULL
'	NULL
``	NULL
C-labeled	NULL
proteins	NULL
myosin	NULL
(	NULL
M	NULL
,	NULL
=	NULL
200,000	NULL
)	NULL
,	NULL
phosphorylase	NULL
b	NULL
(	NULL
M	NULL
,	NULL
=	NULL
97,000	NULL
)	NULL
,	NULL
bovine	NULL
serum	NULL
albumin	NULL
(	NULL
M	NULL
,	NULL
=	NULL
69,000	NULL
)	NULL
,	NULL
ovalbumin	NULL
(	NULL
M	NULL
,	NULL
=	NULL
46,000	NULL
)	NULL
,	NULL
and	NULL
carbonic	NULL
anhydrase	NULL
(	NULL
M	NULL
,	NULL
=	NULL
30,000	NULL
)	NULL
(	NULL
New	NULL
England	NULL
Nuclear	NULL
)	NULL
.	NULL

RESULTS	NULL
Preparation	NULL
of	NULL
Anti-Human	NULL
Glucocorticoid	NULL
Receptor	NULL
Anti-sera	NULL
.	NULL

The	NULL
lymphoid	NULL
cell	NULL
line	NULL
IM-9	NULL
was	NULL
chosen	NULL
as	NULL
a	NULL
source	NULL
of	NULL
human	NULL
glucocorticoid	NULL
receptor	NULL
because	NULL
of	NULL
its	NULL
unusually	NULL
high	NULL
glucocorticoid	NULL
receptor	NULL
concentration	NULL
(	NULL
44	NULL
)	NULL
and	NULL
its	NULL
lack	NULL
of	NULL
receptors	NULL
for	NULL
other	NULL
steroid	NULL
hormones	NULL
(	NULL
32	NULL
)	NULL
.	NULL

Purification	NULL
of	NULL
the	NULL
receptor	NULL
by	NULL
the	NULL
2-stage	NULL
DNA-cellulose	NULL
chromotography	NULL
procedure	NULL
of	NULL
Eisen	NULL
and	NULL
Glinsmann	NULL
(	NULL
7	NULL
)	NULL
yielded	NULL
preparations	NULL
containing	NULL
50	NULL
to	NULL
100	NULL
pmol	NULL
of	NULL
receptor	NULL
which	NULL
were	NULL
calculated	NULL
to	NULL
be	NULL
approximately	NULL
50	NULL
%	NULL
pure	NULL
(	NULL
Table	NULL
1	NULL
)	NULL
.	NULL

When	NULL
these	NULL
receptor	NULL
preparations	NULL
were	NULL
subjected	NULL
to	NULL
gel	NULL
permeation	NULL
chromatography	NULL
on	NULL
Sephacryl	NULL
$	NULL
300	NULL
,	NULL
4541	NULL
Downloaded	NULL
from	NULL
cancerres.aacrjournals.org	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

©	NULL
1984	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
.	NULL

J.	NULL
M.	NULL
Harmon	NULL
et	NULL
al	NULL
.	NULL

a	NULL
major	NULL
peak	NULL
of	NULL
apparent	NULL
Stokes	NULL
'	NULL
radius	NULL
5.6	NULL
to	NULL
6.0	NULL
nm	NULL
was	NULL
observed	NULL
(	NULL
Chart	NULL
1	NULL
)	NULL
.	NULL

This	NULL
was	NULL
indistinguishable	NULL
from	NULL
the	NULL
apparent	NULL
Stokes	NULL
'	NULL
radius	NULL
of	NULL
[	NULL
°HJTA-labeled	NULL
receptors	NULL
in	NULL
crude	NULL
cytosol	NULL
(	NULL
Chart	NULL
1	NULL
)	NULL
and	NULL
is	NULL
virtually	NULL
identical	NULL
to	NULL
the	NULL
apparent	NULL
Stokes	NULL
'	NULL
radius	NULL
of	NULL
highly	NULL
purified	NULL
,	NULL
intact	NULL
,	NULL
rat	NULL
liver	NULL
glucocorticoid	NULL
receptors	NULL
(	NULL
45	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
these	NULL
preparations	NULL
contained	NULL
primarily	NULL
intact	NULL
,	NULL
unproteo-lyzed	NULL
,	NULL
glucocorticoid	NULL
receptors	NULL
.	NULL

However	NULL
,	NULL
a	NULL
smaller	NULL
peak	NULL
of	NULL
=4.0	NULL
nm	NULL
was	NULL
also	NULL
observed	NULL
(	NULL
Chart	NULL
1	NULL
)	NULL
,	NULL
indicating	NULL
that	NULL
some	NULL
partially	NULL
proteolyzed	NULL
receptor	NULL
was	NULL
also	NULL
present	NULL
in	NULL
our	NULL
purified	NULL
prepara-tions	NULL
.	NULL

Despite	NULL
the	NULL
presence	NULL
of	NULL
a	NULL
small	NULL
amount	NULL
of	NULL
partially	NULL
proteolyzed	NULL
receptor	NULL
and	NULL
the	NULL
lack	NULL
of	NULL
homogeneous	NULL
antigen	NULL
,	NULL
these	NULL
preparations	NULL
were	NULL
used	NULL
to	NULL
immunize	NULL
female	NULL
New	NULL
Zealand	NULL
White	NULL
rabbits	NULL
.	NULL

Rabbits	NULL
were	NULL
immunized	NULL
at	NULL
3-	NULL
to	NULL
4-week	NULL
intervals	NULL
,	NULL
and	NULL
the	NULL
presence	NULL
of	NULL
anti-receptor	NULL
antibody	NULL
was	NULL
evaluated	NULL
10	NULL
days	NULL
after	NULL
each	NULL
immunization	NULL
by	NULL
indirect	NULL
precipitation	NULL
of	NULL
receptor-antibody	NULL
complexes	NULL
with	NULL
formalin-fixed	NULL
S.	NULL
aureus	NULL
membranes	NULL
containing	NULL
Protein	NULL
A	NULL
.	NULL

In	NULL
each	NULL
of	NULL
the	NULL
rabbits	NULL
studied	NULL
,	NULL
no	NULL
anti-receptor	NULL
antibody	NULL
activity	NULL
was	NULL
detected	NULL
in	NULL
either	NULL
preimmune	NULL
serum	NULL
or	NULL
serum	NULL
taken	NULL
after	NULL
the	NULL
primary	NULL
immunization	NULL
(	NULL
Chart	NULL
2	NULL
)	NULL
.	NULL

In	NULL
all	NULL
cases	NULL
,	NULL
activity	NULL
was	NULL
detected	NULL
after	NULL
the	NULL
second	NULL
immunization	NULL
,	NULL
and	NULL
a	NULL
further	NULL
increase	NULL
in	NULL
activity	NULL
was	NULL
observed	NULL
after	NULL
the	NULL
third	NULL
immunization	NULL
(	NULL
Chart	NULL
2	NULL
)	NULL
.	NULL

However	NULL
,	NULL
additional	NULL
increases	NULL
in	NULL
activity	NULL
could	NULL
not	NULL
be	NULL
achieved	NULL
with	NULL
additional	NULL
immunization	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Precipitated	NULL
radioactivity	NULL
clearly	NULL
represents	NULL
[	NULL
°H	NULL
]	NULL
JTA	NULL
specifically	NULL
bound	NULL
to	NULL
receptor	NULL
,	NULL
since	NULL
incubation	NULL
of	NULL
receptor	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
10	NULL
um	NULL
unlabeled	NULL
TA	NULL
prior	NULL
to	NULL
incubation	NULL
with	NULL
antibody	NULL
resulted	NULL
in	NULL
compiete	NULL
loss	NULL
of	NULL
radioactivity	NULL
in	NULL
the	NULL
final	NULL
pellet	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Moreover	NULL
,	NULL
the	NULL
ability	NULL
of	NULL
Protein	NULL
A	NULL
to	NULL
adsorb	NULL
the	NULL
steroid-receptor-antibody	NULL
complex	NULL
suggests	NULL
that	NULL
the	NULL
immunoreactive	NULL
Table	NULL
1	NULL
Purification	NULL
of	NULL
IM-9	NULL
glucocorticoid	NULL
receptors	NULL
Receptor	NULL
-	NULL
Yield	NULL
_	NULL
Protein	NULL
Purifica-	NULL
Purity	NULL
Step	NULL
(	NULL
pmon®	NULL
__	NULL
(	NULL
%	NULL
)	NULL
___	NULL
(	NULL
mg	NULL
)	NULL
``	NULL
___	NULL
tion	NULL
(	NULL
fold	NULL
)	NULL
__	NULL
(	NULL
%	NULL
)	NULL
°	NULL
Crude	NULL
cytosol	NULL
314	NULL
100	NULL
82	NULL
1	NULL
0.034	NULL
DNA-Cellulose	NULL
I	NULL
flow	NULL
153	NULL
49	NULL
70	NULL
0.57	NULL
0.020	NULL
through	NULL
DNA-Celtuiose	NULL
II	NULL
eluate	NULL
88	NULL
28	NULL
0.015	NULL
1523	NULL
53	NULL
Hydroxylapatite	NULL
eluate	NULL
73	NULL
23	NULL
0.013	NULL
_	NULL
1457	NULL
51	NULL
Z	NULL
Calculated	NULL
assuming	NULL
one	NULL
steroid	NULL
binding	NULL
site	NULL
per	NULL
receptor	NULL
.	NULL

Proteins	NULL
were	NULL
measured	NULL
by	NULL
the	NULL
method	NULL
of	NULL
Bradford	NULL
(	NULL
2	NULL
)	NULL
.	NULL

©	NULL
Calculated	NULL
on	NULL
the	NULL
basis	NULL
of	NULL
an	NULL
M	NULL
,	NULL
90,000	NULL
receptor	NULL
protein	NULL
.	NULL

A	NULL
B	NULL
Fca	NULL
o	NULL
20	NULL
b	NULL
W	NULL
4	NULL
5	NULL
<	NULL
-	NULL
m	NULL
a	NULL
+	NULL
>	NULL
<	NULL
--	NULL
o	NULL
aa	NULL
<	NULL
n	NULL
a	NULL
MITA	NULL
DPM	NULL
x	NULL
10-3	NULL
as	NULL
&	NULL
pHJtA	NULL
DPM	NULL
x	NULL
10-3	NULL
to	NULL
P3	NULL
``	NULL
**5	NULL
10	NULL
15	NULL
20	NULL
25	NULL
30	NULL
35	NULL
40	NULL
``	NULL
**	NULL
``	NULL
0	NULL
15	NULL
20	NULL
25	NULL
30	NULL
35	NULL
40	NULL
mi	NULL
ELUTED	NULL
ml	NULL
ELUTED	NULL
Chart	NULL
1	NULL
.	NULL

Gel	NULL
filtration	NULL
of	NULL
crude	NULL
and	NULL
purified	NULL
IM-9	NULL
glucocorticoid	NULL
receptors	NULL
.	NULL

[	NULL
PH	NULL
]	NULL
-TA-labeled	NULL
glucocorticoid	NULL
receptors	NULL
were	NULL
chromatographed	NULL
on	NULL
Sephacryl	NULL
$	NULL
300	NULL
either	NULL
prior	NULL
to	NULL
(	NULL
A	NULL
)	NULL
or	NULL
after	NULL
(	NULL
B	NULL
)	NULL
purificaton	NULL
.	NULL

One-ml	NULL
fractions	NULL
were	NULL
collected	NULL
and	NULL
assayed	NULL
for	NULL
radioactivity	NULL
by	NULL
liquid	NULL
scintillation	NULL
methods	NULL
as	NULL
described	NULL
in	NULL
``	NULL
Materials	NULL
and	NULL
Methods	NULL
.	NULL
``	NULL

Columns	NULL
were	NULL
calibrated	NULL
using	NULL
the	NULL
protein	NULL
standards	NULL
thyroglobulin	NULL
(	NULL
V	NULL
,	NULL
=	NULL
16.5	NULL
mi	NULL
)	NULL
,	NULL
ferritin	NULL
(	NULL
F	NULL
,	NULL
V	NULL
,	NULL
=	NULL
18.5	NULL
mi	NULL
)	NULL
,	NULL
catalase	NULL
(	NULL
C	NULL
,	NULL
V	NULL
,	NULL
=	NULL
21.2	NULL
ml	NULL
)	NULL
,	NULL
aldolase	NULL
(	NULL
A	NULL
,	NULL
V	NULL
,	NULL
=	NULL
22.0	NULL
mi	NULL
)	NULL
,	NULL
bovine	NULL
serum	NULL
albumin	NULL
(	NULL
V	NULL
,	NULL
=	NULL
24.0	NULL
mi	NULL
)	NULL
,	NULL
and	NULL
ovalbumin	NULL
(	NULL
O	NULL
,	NULL
V	NULL
,	NULL
=	NULL
26.5	NULL
mi	NULL
)	NULL
.	NULL

4542	NULL
pita	NULL
opm	NULL
x	NULL
10-3	NULL
2	NULL
4	NULL
6	NULL
8	NULL
10	NULL
pl	NULL
SERUM	NULL
Chart	NULL
2	NULL
.	NULL

Time	NULL
course	NULL
of	NULL
immunization	NULL
.	NULL

Rabbits	NULL
882	NULL
and	NULL
884	NULL
were	NULL
immunized	NULL
and	NULL
bled	NULL
as	NULL
described	NULL
in	NULL
``	NULL
Materials	NULL
and	NULL
Methods	NULL
.	NULL
``	NULL

IgG	NULL
anti-receptor	NULL
antibody	NULL
activity	NULL
was	NULL
detected	NULL
by	NULL
incubating	NULL
0.1	NULL
,	NULL
1.0	NULL
,	NULL
or	NULL
10	NULL
«	NULL
I	NULL
of	NULL
serum	NULL
with	NULL
50	NULL
«	NULL
I	NULL
of	NULL
PH	NULL
]	NULL
-TA-labeled	NULL
IM-9	NULL
cytosol	NULL
for	NULL
4	NULL
hr	NULL
followed	NULL
by	NULL
precipitation	NULL
of	NULL
the	NULL
trivalent	NULL
antibody-PHJTA	NULL
receptor	NULL
complex	NULL
with	NULL
Protein	NULL
A.	NULL
Sera	NULL
were	NULL
tested	NULL
prior	NULL
to	NULL
immunization	NULL
(	NULL
&	NULL
A	NULL
)	NULL
,	NULL
10	NULL
days	NULL
after	NULL
the	NULL
primary	NULL
immunization	NULL
(	NULL
@	NULL
)	NULL
,	NULL
10	NULL
days	NULL
after	NULL
the	NULL
first	NULL
booster	NULL
injection	NULL
(	NULL
MA	NULL
,	NULL
or	NULL
10	NULL
days	NULL
after	NULL
the	NULL
second	NULL
booster	NULL
injection	NULL
(	NULL
4	NULL
)	NULL
.	NULL

component	NULL
is	NULL
an	NULL
IgG	NULL
.	NULL

To	NULL
assess	NULL
whether	NULL
there	NULL
was	NULL
a	NULL
direct	NULL
interaction	NULL
between	NULL
antibody	NULL
and	NULL
receptor	NULL
,	NULL
[	NULL
°HJTA-labeled	NULL
SR	NULL
complexes	NULL
incubated	NULL
with	NULL
either	NULL
immune	NULL
or	NULL
nonimmune	NULL
serum	NULL
were	NULL
subjected	NULL
to	NULL
chromatography	NULL
on	NULL
Sephacryl	NULL
S300	NULL
.	NULL

Complexes	NULL
incubated	NULL
with	NULL
nonimmune	NULL
serum	NULL
eluted	NULL
with	NULL
an	NULL
apparent	NULL
Stokes-	NULL
radius	NULL
of	NULL
5.6	NULL
to	NULL
6.0	NULL
nm	NULL
(	NULL
Chart	NULL
3	NULL
)	NULL
.	NULL

This	NULL
is	NULL
indistinguishable	NULL
from	NULL
the	NULL
apparent	NULL
Stokes	NULL
'	NULL
radius	NULL
of	NULL
the	NULL
crude	NULL
or	NULL
highly	NULL
purified	NULL
glucocorticoid	NULL
receptor	NULL
chromatographed	NULL
under	NULL
identical	NULL
conditions	NULL
(	NULL
Chart	NULL
1	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
the	NULL
elution	NULL
profile	NULL
of	NULL
SR	NULL
complexes	NULL
incubated	NULL
with	NULL
immune	NULL
serum	NULL
was	NULL
markedly	NULL
altered	NULL
;	NULL
the	NULL
bulk	NULL
of	NULL
the	NULL
SR	NULL
complexes	NULL
eluted	NULL
in	NULL
the	NULL
void	NULL
volume	NULL
(	NULL
Chart	NULL
3	NULL
)	NULL
,	NULL
indicating	NULL
the	NULL
presence	NULL
of	NULL
antibody-SR	NULL
complexes	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
immune	NULL
serum	NULL
was	NULL
capable	NULL
of	NULL
displacing	NULL
[	NULL
°H	NULL
]	NULL
JTA-receptor	NULL
complexes	NULL
from	NULL
their	NULL
normal	NULL
position	NULL
on	NULL
high-salt	NULL
sucrose	NULL
gradients	NULL
.	NULL

When	NULL
[	NULL
°H	NULL
]	NULL
JTA-receptor	NULL
complexes	NULL
were	NULL
subjected	NULL
to	NULL
sucrose	NULL
density	NULL
gradient	NULL
centrifugation	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
immune	NULL
serum	NULL
,	NULL
a	NULL
3.8S	NULL
peak	NULL
of	NULL
radioactivity	NULL
was	NULL
observed	NULL
(	NULL
Chart	NULL
4	NULL
)	NULL
.	NULL

However	NULL
,	NULL
when	NULL
[	NULL
°HJTA-receptor	NULL
complexes	NULL
were	NULL
incubated	NULL
with	NULL
immune	NULL
serum	NULL
prior	NULL
to	NULL
centrifugation	NULL
,	NULL
the	NULL
resulting	NULL
complexes	NULL
sedimented	NULL
to	NULL
the	NULL
bottom	NULL
of	NULL
the	NULL
centrifuge	NULL
tube	NULL
(	NULL
Chart	NULL
4	NULL
)	NULL
.	NULL

These	NULL
results	NULL
suggest	NULL
that	NULL
not	NULL
only	NULL
is	NULL
there	NULL
a	NULL
direct	NULL
physical	NULL
interaction	NULL
between	NULL
the	NULL
receptor	NULL
and	NULL
the	NULL
antibody	NULL
,	NULL
but	NULL
that	NULL
there	NULL
are	NULL
multiple	NULL
interactions	NULL
.	NULL

Such	NULL
interactions	NULL
could	NULL
be	NULL
between	NULL
a	NULL
single	NULL
species	NULL
of	NULL
antibody	NULL
and	NULL
multiple	NULL
identical	NULL
(	NULL
or	NULL
very	NULL
similar	NULL
)	NULL
antigenic	NULL
sites	NULL
on	NULL
the	NULL
receptor	NULL
,	NULL
or	NULL
they	NULL
could	NULL
be	NULL
between	NULL
multiple	NULL
species	NULL
of	NULL
antibodies	NULL
and	NULL
different	NULL
antigenic	NULL
determinants	NULL
on	NULL
the	NULL
receptor	NULL
.	NULL

Antibody	NULL
Specificity	NULL
.	NULL

The	NULL
specificity	NULL
of	NULL
anti-human	NULL
glucocorticoid	NULL
receptor	NULL
antibodies	NULL
for	NULL
the	NULL
glucocorticoid	NULL
receptors	NULL
of	NULL
CANCER	NULL
RESEARCH	NULL
VOL	NULL
.	NULL

44	NULL
Downloaded	NULL
from	NULL
cancerres.aacrjournals.org	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

©	NULL
1984	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
.	NULL

other	NULL
species	NULL
was	NULL
determined	NULL
by	NULL
Sephacryl	NULL
S300	NULL
chromatography	NULL
of	NULL
[	NULL
°H	NULL
]	NULL
JTA-receptor	NULL
complexes	NULL
prepared	NULL
from	NULL
rat	NULL
liver	NULL
or	NULL
mouse	NULL
S49	NULL
cells	NULL
.	NULL

As	NULL
was	NULL
the	NULL
case	NULL
for	NULL
IM-9	NULL
glucocorticoid	NULL
receptors	NULL
,	NULL
[	NULL
°H	NULL
]	NULL
TA-receptor	NULL
complexes	NULL
prepared	NULL
from	NULL
either	NULL
rat	NULL
liver	NULL
or	NULL
$	NULL
49	NULL
cytosol	NULL
were	NULL
found	NULL
to	NULL
elute	NULL
as	NULL
a	NULL
predominantly	NULL
5.6-	NULL
to	NULL
6.0-nm	NULL
species	NULL
after	NULL
incubation	NULL
with	NULL
nonimmune	NULL
serum	NULL
(	NULL
Chart	NULL
5	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
after	NULL
incubation	NULL
with	NULL
immune	NULL
sera	NULL
,	NULL
the	NULL
[	NULL
°HJTA-receptor	NULL
complexes	NULL
of	NULL
both	NULL
species	NULL
were	NULL
eluted	NULL
in	NULL
the	NULL
void	NULL
volume	NULL
of	NULL
the	NULL
column	NULL
.	NULL

Thus	NULL
,	NULL
anti-human	NULL
glucocorticoid	NULL
receptor	NULL
antibodies	NULL
react	NULL
with	NULL
both	NULL
rat	NULL
liver	NULL
and	NULL
mouse	NULL
lymphoid	NULL
glucocorticoid	NULL
PHJTA	NULL
DPM	NULL
x	NULL
10-3	NULL
Be	NULL
10	NULL
15	NULL
20	NULL
25	NULL
30	NULL
-	NULL
35	NULL
FRACTION	NULL
NUMBER	NULL
Chart	NULL
3	NULL
.	NULL

Gel	NULL
filtration	NULL
of	NULL
antibody-receptor	NULL
complexes	NULL
.	NULL

[	NULL
°H	NULL
]	NULL
TA-labeled	NULL
IM-9	NULL
glucocorticoid	NULL
receptors	NULL
(	NULL
400	NULL
1	NULL
)	NULL
were	NULL
incubated	NULL
with	NULL
100	NULL
Lt	NULL
of	NULL
preimmune	NULL
(	NULL
@	NULL
)	NULL
or	NULL
immune	NULL
(	NULL
&	NULL
)	NULL
serum	NULL
for	NULL
18	NULL
hr	NULL
at	NULL
0-4°	NULL
.	NULL

Samples	NULL
were	NULL
then	NULL
subjected	NULL
to	NULL
chromatography	NULL
on	NULL
Sephacryl	NULL
$	NULL
300	NULL
as	NULL
described	NULL
in	NULL
``	NULL
Materials	NULL
and	NULL
Methods	NULL
.	NULL
``	NULL

One-mi	NULL
fractions	NULL
were	NULL
collected	NULL
and	NULL
assayed	NULL
for	NULL
radioactivity	NULL
.	NULL

Columns	NULL
were	NULL
calibrated	NULL
using	NULL
the	NULL
protein	NULL
standards	NULL
ferritin	NULL
(	NULL
F	NULL
)	NULL
,	NULL
catalase	NULL
(	NULL
C	NULL
)	NULL
,	NULL
aldolase	NULL
(	NULL
4	NULL
)	NULL
,	NULL
and	NULL
ovalbumin	NULL
(	NULL
0	NULL
)	NULL
.	NULL

|	NULL
20	NULL
x	NULL
8F	NULL
81A	NULL
6	NULL
i	NULL
C	NULL
X	NULL
ps	NULL
&	NULL
2	NULL
0	NULL
1	NULL
1	NULL
1	NULL
|	NULL
5	NULL
10	NULL
15	NULL
20	NULL
25	NULL
TOP	NULL
FRACTION	NULL
NUMBER	NULL
BOTTOM	NULL
Chart	NULL
4	NULL
.	NULL

Sucrose	NULL
gradient	NULL
centrifugation	NULL
of	NULL
antibody-receptor	NULL
complexes	NULL
.	NULL

[	NULL
°H	NULL
]	NULL
-TA-labeiedcytosdwasineubated	NULL
in	NULL
the	NULL
presence	NULL
(	NULL
0	NULL
)	NULL
or	NULL
absence	NULL
(	NULL
@	NULL
)	NULL
of	NULL
an	NULL
equal	NULL
volume	NULL
of	NULL
immune	NULL
serum	NULL
for	NULL
4	NULL
hr	NULL
at	NULL
0-4°	NULL
.	NULL

Samples	NULL
were	NULL
subjected	NULL
to	NULL
sucrose	NULL
density	NULL
gradient	NULL
centrifugation	NULL
as	NULL
described	NULL
in	NULL
``	NULL
Materials	NULL
and	NULL
Methods	NULL
``	NULL
and	NULL
gradient	NULL
fractions	NULL
were	NULL
collected	NULL
and	NULL
analyzed	NULL
for	NULL
radioactivity	NULL
.	NULL

**C-labeled	NULL
bovine	NULL
serum	NULL
albumin	NULL
(	NULL
[	NULL
``	NULL
*CJBSA	NULL
)	NULL
was	NULL
included	NULL
in	NULL
each	NULL
gradient	NULL
as	NULL
an	NULL
internal	NULL
standard	NULL
.	NULL

OCTOBER	NULL
1984	NULL
Anti-Human	NULL
Glucocorticoid	NULL
Receptor	NULL
Antibodies	NULL
10	NULL
20	NULL
30	NULL
FRACTION	NULL
NUMBER	NULL
Chart	NULL
5	NULL
.	NULL

Species	NULL
specificity	NULL
of	NULL
anti-human	NULL
glucocorticoid	NULL
receptor	NULL
antibodies	NULL
.	NULL

PH	NULL
]	NULL
JTA-labeled	NULL
cytosols	NULL
(	NULL
250	NULL
«	NULL
!	NULL
)	NULL

prepared	NULL
from	NULL
IM-9	NULL
,	NULL
rat	NULL
liver	NULL
,	NULL
and	NULL
$	NULL
49	NULL
cells	NULL
were	NULL
incubated	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
50	NULL
»	NULL
!	NULL

of	NULL
immune	NULL
(	NULL
0	NULL
)	NULL
or	NULL
nonimmune	NULL
(	NULL
@	NULL
)	NULL
serum	NULL
for	NULL
18	NULL
hr	NULL
at	NULL
0-4°	NULL
.	NULL

After	NULL
removal	NULL
of	NULL
unbound	NULL
steroid	NULL
with	NULL
dextran-coated	NULL
charcoal	NULL
(	NULL
34	NULL
)	NULL
,	NULL
sampbs	NULL
(	NULL
300y0weresubjectedtochrornawgraphymoolunmsofSephacrylsaoo	NULL
as	NULL
described	NULL
in	NULL
``	NULL
Materials	NULL
and	NULL
Methods	NULL
.	NULL
``	NULL

One-m	NULL
!	NULL

fractions	NULL
were	NULL
collected	NULL
and	NULL
analyzed	NULL
for	NULL
radioactivity	NULL
.	NULL

receptors	NULL
.	NULL

However	NULL
,	NULL
after	NULL
incubation	NULL
with	NULL
immune	NULL
serum	NULL
,	NULL
there	NULL
was	NULL
a	NULL
portion	NULL
of	NULL
IM-9	NULL
and	NULL
rat	NULL
liver	NULL
[	NULL
°H	NULL
]	NULL
TA	NULL
complexes	NULL
which	NULL
were	NULL
not	NULL
shifted	NULL
into	NULL
the	NULL
void	NULL
volume	NULL
(	NULL
Chart	NULL
5	NULL
)	NULL
.	NULL

These	NULL
complexes	NULL
eluted	NULL
at	NULL
=	NULL
4.0	NULL
nm	NULL
and	NULL
probably	NULL
represent	NULL
partially	NULL
proteolyzed	NULL
receptor	NULL
.	NULL

Thus	NULL
,	NULL
it	NULL
appears	NULL
that	NULL
anti-human	NULL
glucocorticoid	NULL
receptor	NULL
antibodies	NULL
do	NULL
not	NULL
recognize	NULL
partially	NULL
proteolyzed	NULL
receptor	NULL
.	NULL

These	NULL
results	NULL
also	NULL
suggest	NULL
that	NULL
it	NULL
was	NULL
the	NULL
5.6-	NULL
to	NULL
6.0-nm	NULL
form	NULL
of	NULL
the	NULL
receptor	NULL
against	NULL
which	NULL
antibodies	NULL
were	NULL
raised	NULL
.	NULL

To	NULL
further	NULL
investigate	NULL
the	NULL
nature	NULL
of	NULL
the	NULL
interaction	NULL
between	NULL
these	NULL
antisera	NULL
and	NULL
the	NULL
human	NULL
glucocorticoid	NULL
receptor	NULL
,	NULL
experiments	NULL
were	NULL
performed	NULL
on	NULL
cytosols	NULL
labeled	NULL
with	NULL
[	NULL
°HJDM	NULL
.	NULL

We	NULL
have	NULL
shown	NULL
previously	NULL
that	NULL
this	NULL
electrophilic	NULL
affinity	NULL
label	NULL
forms	NULL
a	NULL
covalent	NULL
attachment	NULL
to	NULL
rat	NULL
liver	NULL
and	NULL
HTC	NULL
cell	NULL
glucocorticoid	NULL
receptors	NULL
(	NULL
8	NULL
,	NULL
38	NULL
,	NULL
39	NULL
)	NULL
,	NULL
presumably	NULL
through	NULL
the	NULL
formation	NULL
of	NULL
a	NULL
thioether	NULL
linkage	NULL
with	NULL
a	NULL
sulfhydryl	NULL
group	NULL
at	NULL
or	NULL
near	NULL
the	NULL
steroid	NULL
binding	NULL
site	NULL
(	NULL
37	NULL
,	NULL
39	NULL
)	NULL
.	NULL

When	NULL
crude	NULL
,	NULL
unfractionated	NULL
cytosol	NULL
was	NULL
incubated	NULL
with	NULL
200	NULL
nm	NULL
[	NULL
°HJDM	NULL
and	NULL
then	NULL
subjected	NULL
to	NULL
SDS-PAGE	NULL
,	NULL
the	NULL
results	NULL
presented	NULL
in	NULL
Fig	NULL
.	NULL

1	NULL
were	NULL
obtained	NULL
.	NULL

Although	NULL
at	NULL
least	NULL
25	NULL
distinct	NULL
components	NULL
could	NULL
be	NULL
resolved	NULL
,	NULL
the	NULL
major	NULL
[	NULL
PHJDM-labeled	NULL
component	NULL
had	NULL
an	NULL
apparent	NULL
molecular	NULL
weight	NULL
of	NULL
approximately	NULL
90,000	NULL
.	NULL

This	NULL
is	NULL
nearly	NULL
identical	NULL
to	NULL
the	NULL
molecular	NULL
weights	NULL
determined	NULL
previously	NULL
by	NULL
SDS-PAGE	NULL
for	NULL
the	NULL
activated	NULL
or	NULL
affinity-labeled	NULL
rat	NULL
liver	NULL
,	NULL
HTC	NULL
cell	NULL
,	NULL
and	NULL
mouse	NULL
lymphoma	NULL
glucocorticoid	NULL
receptors	NULL
(	NULL
11	NULL
,	NULL
26	NULL
,	NULL
38	NULL
,	NULL
45	NULL
)	NULL
.	NULL

inclusion	NULL
of	NULL
10	NULL
um	NULL
labeled	NULL
TA	NULL
during	NULL
the	NULL
incubation	NULL
to	NULL
compete	NULL
for	NULL
specific	NULL
[	NULL
°HJDM	NULL
binding	NULL
to	NULL
receptor	NULL
completely	NULL
abolished	NULL
the	NULL
labeling	NULL
of	NULL
the	NULL
M	NULL
,	NULL
90,000	NULL
component	NULL
,	NULL
strongly	NULL
suggesting	NULL
that	NULL
this	NULL
component	NULL
is	NULL
indeed	NULL
the	NULL
reduced	NULL
,	NULL
denatured	NULL
,	NULL
steroid	NULL
binding	NULL
component	NULL
of	NULL
the	NULL
human	NULL
glucocorticoid	NULL
receptor	NULL
.	NULL

In	NULL
addition	NULL
to	NULL
the	NULL
elimination	NULL
4543	NULL
Downloaded	NULL
from	NULL
cancerres.aacrjournals.org	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

©	NULL
1984	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
.	NULL

J.	NULL
M.	NULL
Harmon	NULL
et	NULL
al	NULL
.	NULL

of	NULL
the	NULL
major	NULL
M	NULL
,	NULL
90,000	NULL
component	NULL
,	NULL
3	NULL
other	NULL
less	NULL
intensely	NULL
[	NULL
°H	NULL
}	NULL
-DM-labeled	NULL
bands	NULL
were	NULL
also	NULL
eliminated	NULL
by	NULL
the	NULL
inclusion	NULL
of	NULL
unlabeled	NULL
TA	NULL
during	NULL
the	NULL
labeling	NULL
reaction	NULL
.	NULL

These	NULL
components	NULL
had	NULL
molecular	NULL
weights	NULL
of	NULL
approximately	NULL
78,000	NULL
,	NULL
51,000	NULL
,	NULL
and	NULL
38,500	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
.	NULL

Based	NULL
on	NULL
the	NULL
known	NULL
susceptibility	NULL
of	NULL
glucocorticoid	NULL
receptors	NULL
to	NULL
proteolysis	NULL
(	NULL
4	NULL
,	NULL
5	NULL
,	NULL
35	NULL
,	NULL
36	NULL
,	NULL
41	NULL
,	NULL
42	NULL
)	NULL
,	NULL
it	NULL
is	NULL
possible	NULL
that	NULL
these	NULL
minor	NULL
competable	NULL
components	NULL
represent	NULL
small	NULL
amounts	NULL
of	NULL
proteolyzed	NULL
receptor	NULL
.	NULL

After	NULL
immunoprecipitation	NULL
of	NULL
[	NULL
°H	NULL
]	NULL
JDM-labeled	NULL
cytosols	NULL
with	NULL
immune	NULL
serum	NULL
,	NULL
only	NULL
2	NULL
components	NULL
could	NULL
be	NULL
identified	NULL
by	NULL
SDS-PAGE	NULL
(	NULL
Fig	NULL
.	NULL

18	NULL
)	NULL
.	NULL

The	NULL
major	NULL
component	NULL
was	NULL
the	NULL
M	NULL
,	NULL
90,000	NULL
protein	NULL
already	NULL
identified	NULL
as	NULL
the	NULL
major	NULL
[	NULL
°HJDM-labeled	NULL
band	NULL
in	NULL
crude	NULL
cytosol	NULL
.	NULL

The	NULL
second	NULL
minor	NULL
component	NULL
had	NULL
a	NULL
molecular	NULL
weight	NULL
of	NULL
78,000	NULL
and	NULL
most	NULL
probably	NULL
represents	NULL
the	NULL
largest	NULL
of	NULL
the	NULL
3	NULL
minor	NULL
competable	NULL
[	NULL
°HJDM-labeled	NULL
bands	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
neither	NULL
the	NULL
M	NULL
,	NULL
51,000	NULL
nor	NULL
the	NULL
M	NULL
,	NULL
38,500	NULL
component	NULL
was	NULL
detectable	NULL
after	NULL
precipitation	NULL
of	NULL
[	NULL
°HJDM-labeled	NULL
cytosol	NULL
with	NULL
immune	NULL
serum	NULL
.	NULL

Even	NULL
after	NULL
film	NULL
exposures	NULL
of	NULL
up	NULL
to	NULL
3	NULL
months	NULL
,	NULL
there	NULL
was	NULL
no	NULL
evidence	NULL
that	NULL
these	NULL
components	NULL
were	NULL
recognized	NULL
by	NULL
immune	NULL
serum	NULL
.	NULL

No	NULL
[	NULL
°HJDM-labeled	NULL
proteins	NULL
were	NULL
detectable	NULL
after	NULL
SDS-PAGE	NULL
of	NULL
[	NULL
PH	NULL
]	NULL
JDM-labeled	NULL
cytosols	NULL
immunoprecipitated	NULL
with	NULL
either	NULL
preimmune	NULL
or	NULL
nonimmune	NULL
sera	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
serum	NULL
obtained	NULL
from	NULL
mock-immunized	NULL
animals	NULL
was	NULL
incapable	NULL
of	NULL
precipitating	NULL
any	NULL
[	NULL
°HJDM-labeled	NULL
material	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
the	NULL
combination	NULL
of	NULL
affinity	NULL
labeling	NULL
and	NULL
immunoprecipitation	NULL
appears	NULL
to	NULL
resolve	NULL
a	NULL
major	NULL
component	NULL
with	NULL
a	NULL
molecular	NULL
weight	NULL
of	NULL
~90,000	NULL
which	NULL
almost	NULL
certainly	NULL
represents	NULL
the	NULL
reduced	NULL
denatured	NULL
form	NULL
of	NULL
the	NULL
IM-9	NULL
glucocorticoid	NULL
receptor	NULL
.	NULL

Identification	NULL
of	NULL
Human	NULL
Leukemic	NULL
Glucocorticoid	NULL
Receptors	NULL
.	NULL

Having	NULL
established	NULL
that	NULL
antibodies	NULL
prepared	NULL
against	NULL
IM-9	NULL
glucocorticoid	NULL
receptors	NULL
could	NULL
be	NULL
used	NULL
in	NULL
conjunction	NULL
with	NULL
affinity	NULL
labeling	NULL
to	NULL
specifically	NULL
identify	NULL
IM-9	NULL
glucocorticoid	NULL
receptors	NULL
,	NULL
the	NULL
glucocorticoid	NULL
receptors	NULL
of	NULL
the	NULL
human	NULL
leukemic	NULL
cell	NULL
line	NULL
CEM-C7	NULL
were	NULL
subjected	NULL
to	NULL
similar	NULL
analysis	NULL
.	NULL

Fig	NULL
.	NULL

2	NULL
shows	NULL
the	NULL
results	NULL
of	NULL
SDS-PAGE	NULL
of	NULL
affinity-labeled	NULL
cytosols	NULL
prepared	NULL
from	NULL
CEM-C7	NULL
.	NULL

In	NULL
contrast	NULL
to	NULL
the	NULL
results	NULL
obtained	NULL
with	NULL
IM-9	NULL
,	NULL
a	NULL
larger	NULL
number	NULL
of	NULL
components	NULL
appears	NULL
to	NULL
be	NULL
labeled	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
while	NULL
a	NULL
partially	NULL
competable	NULL
band	NULL
with	NULL
a	NULL
molecular	NULL
weight	NULL
of	NULL
~90,000	NULL
can	NULL
be	NULL
seen	NULL
,	NULL
this	NULL
band	NULL
is	NULL
not	NULL
the	NULL
dominant	NULL
labeled	NULL
species	NULL
(	NULL
Fig	NULL
.	NULL

24	NULL
)	NULL
.	NULL

These	NULL
differences	NULL
most	NULL
probably	NULL
reflect	NULL
the	NULL
fact	NULL
that	NULL
CEM-C7	NULL
has	NULL
only	NULL
15	NULL
to	NULL
20	NULL
%	NULL
of	NULL
the	NULL
receptor	NULL
concentration	NULL
of	NULL
IM-9	NULL
.	NULL

However	NULL
,	NULL
after	NULL
immunoprecipitation	NULL
of	NULL
[	NULL
°H	NULL
]	NULL
JDM-labeled	NULL
CEM-C7	NULL
cytosol	NULL
with	NULL
immune	NULL
serum	NULL
,	NULL
a	NULL
major	NULL
labeled	NULL
component	NULL
with	NULL
a	NULL
molecular	NULL
weight	NULL
of	NULL
~90,000	NULL
is	NULL
clearly	NULL
evident	NULL
(	NULL
Fig	NULL
.	NULL

2B	NULL
)	NULL
.	NULL

The	NULL
labeling	NULL
of	NULL
this	NULL
component	NULL
was	NULL
completely	NULL
blocked	NULL
by	NULL
the	NULL
inclusion	NULL
of	NULL
10	NULL
um	NULL
unlabeled	NULL
TA	NULL
during	NULL
the	NULL
labeling	NULL
reaction	NULL
.	NULL

Moreover	NULL
,	NULL
no	NULL
such	NULL
component	NULL
was	NULL
visible	NULL
after	NULL
precipitation	NULL
of	NULL
[	NULL
°H	NULL
]	NULL
JDM-labeled	NULL
CEM-C7	NULL
cytosol	NULL
with	NULL
nonimmune	NULL
serum	NULL
(	NULL
Fig	NULL
.	NULL

2B	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
this	NULL
component	NULL
almost	NULL
certainly	NULL
represents	NULL
the	NULL
glucocorticoid	NULL
receptor	NULL
of	NULL
CEM-C7	NULL
cells	NULL
.	NULL

Additional	NULL
evidence	NULL
that	NULL
this	NULL
is	NULL
the	NULL
case	NULL
was	NULL
obtained	NULL
from	NULL
[	NULL
°H	NULL
]	NULL
JDM-labeled	NULL
cytosols	NULL
prepared	NULL
from	NULL
the	NULL
glucocorticoid	NULL
receptor-deficient	NULL
mutant	NULL
ICR-27	NULL
.	NULL

When	NULL
affinity-labeled	NULL
cytosols	NULL
prepared	NULL
from	NULL
this	NULL
mutant	NULL
were	NULL
subjected	NULL
to	NULL
SDS-PAGE	NULL
following	NULL
immunoprecipitation	NULL
,	NULL
the	NULL
presence	NULL
of	NULL
the	NULL
M	NULL
,	NULL
90,000	NULL
copmponent	NULL
was	NULL
significantly	NULL
reduced	NULL
(	NULL
Fig	NULL
.	NULL

2C	NULL
)	NULL
.	NULL

From	NULL
these	NULL
data	NULL
,	NULL
we	NULL
conclude	NULL
that	NULL
the	NULL
antisera	NULL
prepared	NULL
against	NULL
IM-9	NULL
glucocorticoid	NULL
receptors	NULL
are	NULL
capable	NULL
,	NULL
when	NULL
used	NULL
in	NULL
conjunction	NULL
with	NULL
affinity	NULL
labeling	NULL
,	NULL
of	NULL
providing	NULL
unequivocal	NULL
identification	NULL
of	NULL
human	NULL
glucocorticoid	NULL
receptors	NULL
even	NULL
when	NULL
such	NULL
receptors	NULL
are	NULL
present	NULL
in	NULL
extremely	NULL
low	NULL
amounts	NULL
.	NULL

4544	NULL
Although	NULL
immunoprecipitates	NULL
of	NULL
affinity-labeled	NULL
CEM	NULL
cell	NULL
receptor	NULL
contained	NULL
contaminating	NULL
protein	NULL
species	NULL
not	NULL
seen	NULL
with	NULL
affinity-labeled	NULL
IM-9	NULL
receptors	NULL
,	NULL
these	NULL
contaminating	NULL
proteins	NULL
were	NULL
present	NULL
even	NULL
when	NULL
nonimmune	NULL
sera	NULL
were	NULL
used	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
,	NULL
B	NULL
and	NULL
C	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
they	NULL
appear	NULL
to	NULL
be	NULL
the	NULL
result	NULL
of	NULL
nonspecific	NULL
trapping	NULL
.	NULL

The	NULL
fact	NULL
that	NULL
CEM	NULL
cells	NULL
contain	NULL
only	NULL
15	NULL
to	NULL
20	NULL
%	NULL
of	NULL
the	NULL
receptor	NULL
concentration	NULL
of	NULL
IM-9	NULL
(	NULL
15,000	NULL
to	NULL
20,000	NULL
versus	NULL
100,000	NULL
recep-tors/cell	NULL
)	NULL
and	NULL
the	NULL
fact	NULL
that	NULL
[	NULL
°HJDM	NULL
appears	NULL
to	NULL
label	NULL
a	NULL
much	NULL
larger	NULL
number	NULL
of	NULL
proteins	NULL
in	NULL
CEM	NULL
cytosols	NULL
than	NULL
in	NULL
IM-9	NULL
cytosols	NULL
may	NULL
account	NULL
for	NULL
the	NULL
presence	NULL
of	NULL
these	NULL
components	NULL
.	NULL

The	NULL
difference	NULL
in	NULL
the	NULL
intensity	NULL
of	NULL
the	NULL
major	NULL
contaminating	NULL
protein	NULL
seen	NULL
in	NULL
comparing	NULL
Fig	NULL
.	NULL

2	NULL
,	NULL
B	NULL
and	NULL
C	NULL
,	NULL
is	NULL
most	NULL
probably	NULL
the	NULL
result	NULL
of	NULL
clonal	NULL
variation	NULL
.	NULL

Equal	NULL
amounts	NULL
of	NULL
CEM-C7	NULL
and	NULL
ICR-27	NULL
cytosol	NULL
were	NULL
used	NULL
for	NULL
the	NULL
experiments	NULL
presented	NULL
in	NULL
Fig	NULL
.	NULL

2	NULL
,	NULL
B	NULL
and	NULL
C	NULL
,	NULL
and	NULL
the	NULL
data	NULL
presented	NULL
are	NULL
from	NULL
a	NULL
single	NULL
gel	NULL
and	NULL
a	NULL
single	NULL
piece	NULL
of	NULL
film	NULL
.	NULL

Moreover	NULL
,	NULL
there	NULL
are	NULL
no	NULL
obvious	NULL
differences	NULL
in	NULL
the	NULL
relative	NULL
amounts	NULL
of	NULL
other	NULL
minor	NULL
contaminating	NULL
proteins	NULL
seen	NULL
in	NULL
Fig	NULL
.	NULL

2	NULL
,	NULL
B	NULL
and	NULL
C.	NULL
DISCUSSION	NULL
We	NULL
have	NULL
reported	NULL
previously	NULL
the	NULL
ability	NULL
of	NULL
antibodies	NULL
raised	NULL
against	NULL
the	NULL
rat	NULL
liver	NULL
glucocorticoid	NULL
receptor	NULL
,	NULL
in	NULL
combination	NULL
with	NULL
the	NULL
covalent	NULL
affinity	NULL
ligand	NULL
[	NULL
°HJDM	NULL
,	NULL
to	NULL
provide	NULL
unequivocal	NULL
identification	NULL
of	NULL
the	NULL
glucocorticoid	NULL
receptor	NULL
in	NULL
crude	NULL
rat	NULL
liver	NULL
and	NULL
HTC	NULL
cell	NULL
cytosols	NULL
(	NULL
8	NULL
,	NULL
38	NULL
)	NULL
.	NULL

Similar	NULL
analysis	NULL
of	NULL
human	NULL
glucocorticoid	NULL
receptors	NULL
has	NULL
been	NULL
hampered	NULL
by	NULL
the	NULL
poor	NULL
cross-reactivity	NULL
of	NULL
antibodies	NULL
raised	NULL
against	NULL
the	NULL
rat	NULL
liver	NULL
glucocorticoid	NULL
receptor	NULL
with	NULL
human	NULL
glucocorticoid	NULL
receptors	NULL
(	NULL
Footnote	NULL
5	NULL
;	NULL
Ref	NULL
.	NULL

40	NULL
)	NULL
.	NULL

We	NULL
have	NULL
now	NULL
prepared	NULL
antisera	NULL
against	NULL
highly	NULL
purified	NULL
preparations	NULL
of	NULL
human	NULL
lymphoblast	NULL
glucocorticoid	NULL
receptors	NULL
.	NULL

Antibodies	NULL
prepared	NULL
from	NULL
both	NULL
rabbits	NULL
are	NULL
IgGs	NULL
as	NULL
demonstrated	NULL
by	NULL
the	NULL
ability	NULL
of	NULL
S.	NULL
aureus	NULL
Protein	NULL
A	NULL
to	NULL
adsorb	NULL
SR	NULL
complexes	NULL
(	NULL
18	NULL
)	NULL
.	NULL

in	NULL
addition	NULL
,	NULL
the	NULL
nearly	NULL
identical	NULL
time	NULL
courses	NULL
of	NULL
immunization	NULL
for	NULL
2	NULL
rabbits	NULL
suggest	NULL
that	NULL
the	NULL
production	NULL
of	NULL
antibody	NULL
in	NULL
response	NULL
to	NULL
immunization	NULL
is	NULL
a	NULL
reproducible	NULL
phenomenon	NULL
.	NULL

However	NULL
,	NULL
neither	NULL
rabbit	NULL
yielded	NULL
a	NULL
high-titer	NULL
serum	NULL
.	NULL

In	NULL
most	NULL
cases	NULL
,	NULL
10	NULL
ul	NULL
of	NULL
undiluted	NULL
serum	NULL
were	NULL
required	NULL
for	NULL
maximum	NULL
precipitation	NULL
of	NULL
the	NULL
1	NULL
pmol	NULL
of	NULL
receptor	NULL
contained	NULL
in	NULL
50	NULL
ul	NULL
of	NULL
crude	NULL
cytosol	NULL
.	NULL

This	NULL
was	NULL
probably	NULL
the	NULL
result	NULL
of	NULL
the	NULL
small	NULL
amount	NULL
(	NULL
50	NULL
to	NULL
80	NULL
pmol	NULL
)	NULL
of	NULL
receptor	NULL
used	NULL
for	NULL
each	NULL
immunization	NULL
.	NULL

It	NULL
is	NULL
also	NULL
possible	NULL
that	NULL
the	NULL
receptor	NULL
is	NULL
a	NULL
poor	NULL
antigen	NULL
,	NULL
since	NULL
previous	NULL
studies	NULL
using	NULL
much	NULL
greater	NULL
amounts	NULL
of	NULL
rat	NULL
liver	NULL
receptor	NULL
gave	NULL
similar	NULL
low-titer	NULL
sera	NULL
(	NULL
6	NULL
,	NULL
11	NULL
,	NULL
27	NULL
)	NULL
.	NULL

Nevertheless	NULL
,	NULL
immune	NULL
IgG	NULL
was	NULL
capable	NULL
of	NULL
interacting	NULL
directly	NULL
with	NULL
the	NULL
occupied	NULL
glucocorticoid	NULL
receptor	NULL
to	NULL
produce	NULL
a	NULL
shift	NULL
in	NULL
the	NULL
elution	NULL
position	NULL
of	NULL
[	NULL
°H	NULL
]	NULL
JTA-labeled	NULL
receptor	NULL
from	NULL
a	NULL
Sephacryl	NULL
$	NULL
300	NULL
column	NULL
as	NULL
well	NULL
as	NULL
displacement	NULL
of	NULL
[	NULL
°H	NULL
]	NULL
JTA-receptor	NULL
complexes	NULL
on	NULL
sucrose	NULL
density	NULL
gradients	NULL
.	NULL

It	NULL
is	NULL
this	NULL
ability	NULL
to	NULL
produce	NULL
an	NULL
alteration	NULL
in	NULL
the	NULL
physical	NULL
behavior	NULL
of	NULL
SR	NULL
complexes	NULL
which	NULL
has	NULL
heretofore	NULL
been	NULL
the	NULL
principal	NULL
means	NULL
of	NULL
demonstrating	NULL
the	NULL
presence	NULL
of	NULL
anti-SR	NULL
antibodies	NULL
(	NULL
6	NULL
,	NULL
10-14	NULL
,	NULL
22	NULL
,	NULL
27	NULL
,	NULL
30	NULL
,	NULL
31	NULL
,	NULL
43	NULL
)	NULL
.	NULL

Of	NULL
particular	NULL
importance	NULL
is	NULL
the	NULL
ability	NULL
of	NULL
anti-human	NULL
receptor	NULL
antibodies	NULL
to	NULL
selectively	NULL
identify	NULL
affinity-labeled	NULL
glucocorticoid	NULL
receptors	NULL
.	NULL

Since	NULL
only	NULL
partially	NULL
purified	NULL
antigen	NULL
was	NULL
used	NULL
in	NULL
the	NULL
immunization	NULL
,	NULL
we	NULL
did	NULL
not	NULL
expect	NULL
the	NULL
resulting	NULL
antibodies	NULL
to	NULL
react	NULL
with	NULL
only	NULL
the	NULL
glucocorticoid	NULL
receptor	NULL
.	NULL

indeed	NULL
,	NULL
in	NULL
western	NULL
blots	NULL
of	NULL
IM-9	NULL
proteins	NULL
,	NULL
several	NULL
nonreceptor	NULL
proteins	NULL
are	NULL
recognized	NULL
by	NULL
our	NULL
antisera	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

However	NULL
,	NULL
among	NULL
all	NULL
of	NULL
the	NULL
IM-9	NULL
cytosolic	NULL
proteins	NULL
labeled	NULL
by	NULL
[	NULL
°HJDM	NULL
,	NULL
only	NULL
2	NULL
components	NULL
(	NULL
M	NULL
,	NULL
CANCER	NULL
RESEARCH	NULL
VOL	NULL
.	NULL

44	NULL
Downloaded	NULL
from	NULL
cancerres.aacrjournals.org	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

©	NULL
1984	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
.	NULL

90,000	NULL
and	NULL
78,000	NULL
)	NULL
reacted	NULL
with	NULL
immune	NULL
serum	NULL
.	NULL

Several	NULL
lines	NULL
of	NULL
evidence	NULL
indicate	NULL
that	NULL
the	NULL
M	NULL
,	NULL
90,000	NULL
component	NULL
is	NULL
the	NULL
reduced	NULL
denatured	NULL
steroid	NULL
binding	NULL
subunit	NULL
of	NULL
the	NULL
glucocorticoid	NULL
receptor	NULL
.	NULL

The	NULL
M	NULL
,	NULL
90,000	NULL
component	NULL
identified	NULL
in	NULL
IM-9	NULL
cytosols	NULL
was	NULL
the	NULL
most	NULL
extensively	NULL
labeled	NULL
by	NULL
[	NULL
°HJDM	NULL
,	NULL
and	NULL
this	NULL
labeling	NULL
was	NULL
completely	NULL
abolished	NULL
by	NULL
the	NULL
addition	NULL
of	NULL
unlabeled	NULL
steroid	NULL
.	NULL

This	NULL
component	NULL
had	NULL
the	NULL
same	NULL
approximate	NULL
molecular	NULL
weight	NULL
as	NULL
did	NULL
highly	NULL
purified	NULL
rat	NULL
liver	NULL
glucocorticoid	NULL
receptor	NULL
and	NULL
affinity-labeled	NULL
rat	NULL
liver	NULL
,	NULL
HTC	NULL
cell	NULL
,	NULL
and	NULL
mouse	NULL
lymphoma	NULL
glucocorticoid	NULL
receptor	NULL
(	NULL
8	NULL
,	NULL
10	NULL
,	NULL
11	NULL
,	NULL
26	NULL
,	NULL
38	NULL
,	NULL
39	NULL
,	NULL
45	NULL
)	NULL
.	NULL

Immunoprecipitation	NULL
of	NULL
this	NULL
component	NULL
was	NULL
dependent	NULL
on	NULL
the	NULL
presence	NULL
of	NULL
immune	NULL
serum	NULL
,	NULL
and	NULL
the	NULL
labeling	NULL
of	NULL
the	NULL
immunoprecipitated	NULL
M	NULL
,	NULL
90,000	NULL
component	NULL
was	NULL
competable	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
the	NULL
fact	NULL
that	NULL
the	NULL
presence	NULL
of	NULL
this	NULL
component	NULL
was	NULL
markedly	NULL
diminished	NULL
in	NULL
cytosols	NULL
prepared	NULL
from	NULL
the	NULL
receptor-deficient	NULL
mutant	NULL
ICR-27	NULL
provides	NULL
strong	NULL
circumstantial	NULL
evidence	NULL
that	NULL
the	NULL
M	NULL
,	NULL
90,000	NULL
component	NULL
is	NULL
indeed	NULL
the	NULL
reduced	NULL
denatured	NULL
steroid	NULL
binding	NULL
component	NULL
human	NULL
glucocorticoid	NULL
receptor	NULL
.	NULL

Calculation	NULL
of	NULL
the	NULL
molecular	NULL
weight	NULL
of	NULL
IM-9	NULL
glucocorticoid	NULL
receptors	NULL
from	NULL
the	NULL
hydrodynamic	NULL
properties	NULL
of	NULL
[	NULL
°HJTA-labeled	NULL
receptors	NULL
(	NULL
Charts	NULL
1	NULL
and	NULL
4	NULL
)	NULL
suggests	NULL
that	NULL
the	NULL
receptor	NULL
monomer	NULL
has	NULL
a	NULL
molecular	NULL
weight	NULL
of	NULL
approximately	NULL
90,000	NULL
.	NULL

This	NULL
is	NULL
in	NULL
excellent	NULL
agreement	NULL
with	NULL
the	NULL
results	NULL
obtained	NULL
from	NULL
SDS-PAGE	NULL
of	NULL
the	NULL
affinity-labeled	NULL
receptor	NULL
.	NULL

Thus	NULL
,	NULL
all	NULL
of	NULL
the	NULL
data	NULL
are	NULL
consistent	NULL
with	NULL
the	NULL
conclusion	NULL
that	NULL
the	NULL
antibodies	NULL
generated	NULL
against	NULL
partially	NULL
purified	NULL
preparations	NULL
of	NULL
IM-9	NULL
glucocorticoid	NULL
receptors	NULL
are	NULL
capable	NULL
of	NULL
providing	NULL
unequivocal	NULL
identification	NULL
of	NULL
the	NULL
human	NULL
glucocorticoid	NULL
receptor	NULL
.	NULL

Antibodies	NULL
raised	NULL
against	NULL
IM-9	NULL
glucocorticoid	NULL
receptors	NULL
also	NULL
recognized	NULL
CEM	NULL
cell	NULL
glucocorticoid	NULL
receptors	NULL
.	NULL

After	NULL
affinity	NULL
labeling	NULL
and	NULL
immunoprecipitation	NULL
of	NULL
CEM-C7	NULL
receptors	NULL
,	NULL
a	NULL
distinct	NULL
band	NULL
with	NULL
a	NULL
molecular	NULL
weight	NULL
of	NULL
90,000	NULL
was	NULL
easily	NULL
resolved	NULL
.	NULL

This	NULL
was	NULL
identical	NULL
to	NULL
the	NULL
molecular	NULL
weight	NULL
determined	NULL
for	NULL
IM-9	NULL
glucocorticoid	NULL
receptors	NULL
and	NULL
is	NULL
also	NULL
the	NULL
same	NULL
as	NULL
reported	NULL
recently	NULL
for	NULL
affinity-labeled	NULL
glucocorticoid	NULL
receptors	NULL
in	NULL
cells	NULL
isolated	NULL
directly	NULL
from	NULL
patients	NULL
with	NULL
acute	NULL
lymphoblastic	NULL
leukemia	NULL
or	NULL
malignant	NULL
|ymphoma	NULL
(	NULL
9	NULL
)	NULL
.	NULL

Surprisingly	NULL
,	NULL
when	NULL
ICR-27	NULL
cytosols	NULL
were	NULL
affinity	NULL
labeled	NULL
and	NULL
immunoprecipitated	NULL
,	NULL
a	NULL
band	NULL
with	NULL
a	NULL
molecular	NULL
weight	NULL
of	NULL
90,000	NULL
was	NULL
easily	NULL
identifiable	NULL
.	NULL

By	NULL
standard	NULL
labeling	NULL
criteria	NULL
,	NULL
these	NULL
cells	NULL
contain	NULL
less	NULL
than	NULL
500	NULL
receptors	NULL
per	NULL
cell	NULL
(	NULL
16	NULL
)	NULL
.	NULL

The	NULL
fact	NULL
that	NULL
labeling	NULL
of	NULL
this	NULL
band	NULL
was	NULL
competable	NULL
and	NULL
that	NULL
its	NULL
presence	NULL
was	NULL
immune	NULL
serum	NULL
dependent	NULL
indicates	NULL
that	NULL
this	NULL
band	NULL
indeed	NULL
represents	NULL
receptors	NULL
.	NULL

Thus	NULL
,	NULL
the	NULL
combination	NULL
of	NULL
affinity	NULL
labeling	NULL
and	NULL
immunoprecipitation	NULL
using	NULL
anti-human	NULL
glucocorticoid	NULL
receptor	NULL
antibodies	NULL
provides	NULL
an	NULL
extremently	NULL
powerful	NULL
method	NULL
for	NULL
the	NULL
analysis	NULL
of	NULL
small	NULL
quantities	NULL
of	NULL
human	NULL
glucocorticoid	NULL
receptors	NULL
.	NULL

It	NULL
is	NULL
interesting	NULL
to	NULL
note	NULL
that	NULL
the	NULL
antisera	NULL
prepared	NULL
against	NULL
IM-9	NULL
glucocorticoid	NULL
receptors	NULL
appear	NULL
to	NULL
weakly	NULL
recognize	NULL
a	NULL
competable	NULL
[	NULL
°HJDM-labeled	NULL
component	NULL
with	NULL
a	NULL
molecular	NULL
weight	NULL
of	NULL
78,000	NULL
but	NULL
not	NULL
2	NULL
other	NULL
smaller	NULL
competable	NULL
[	NULL
°HJDM-labeled	NULL
components	NULL
with	NULL
molecular	NULL
weights	NULL
of	NULL
51,000	NULL
and	NULL
38,500	NULL
.	NULL

At	NULL
this	NULL
point	NULL
,	NULL
we	NULL
can	NULL
not	NULL
determine	NULL
whether	NULL
these	NULL
components	NULL
are	NULL
proteolytic	NULL
fragments	NULL
derived	NULL
from	NULL
the	NULL
M	NULL
,	NULL
90,000	NULL
receptor	NULL
or	NULL
whether	NULL
they	NULL
represent	NULL
other	NULL
proteins	NULL
which	NULL
display	NULL
saturable	NULL
binding	NULL
of	NULL
[	NULL
°HJDM	NULL
.	NULL

However	NULL
,	NULL
these	NULL
results	NULL
are	NULL
analogous	NULL
to	NULL
those	NULL
reported	NULL
for	NULL
anti-rat	NULL
liver	NULL
glucocorticoid	NULL
receptor	NULL
antibodies	NULL
.	NULL

Caristedt-Duke	NULL
et	NULL
al	NULL
.	NULL

(	NULL
3	NULL
)	NULL
have	NULL
reported	NULL
that	NULL
their	NULL
antibody	NULL
preparations	NULL
did	NULL
not	NULL
recognize	NULL
the	NULL
steroid	NULL
binding	NULL
domain	NULL
of	NULL
the	NULL
rat	NULL
liver	NULL
glucocorticoid	NULL
receptor	NULL
after	NULL
partial	NULL
proteolysis	NULL
.	NULL

Okret	NULL
et	NULL
al	NULL
.	NULL

(	NULL
28	NULL
)	NULL
and	NULL
Stevens	NULL
et	NULL
al	NULL
.	NULL

(	NULL
40	NULL
)	NULL
have	NULL
reported	NULL
that	NULL
the	NULL
anti-rat	NULL
OCTOBER	NULL
1984	NULL
Anti-Human	NULL
Glucocorticoid	NULL
Receptor	NULL
Antibodies	NULL
liver	NULL
glucocorticoid	NULL
receptor	NULL
did	NULL
not	NULL
recognize	NULL
glucocorticoid	NULL
receptors	NULL
derived	NULL
from	NULL
corticosteroid-resistant	NULL
P1798	NULL
cells	NULL
.	NULL

These	NULL
receptors	NULL
are	NULL
apparently	NULL
smaller	NULL
than	NULL
the	NULL
glucocorticoid	NULL
receptors	NULL
of	NULL
corticosteroid-sensitive	NULL
cells	NULL
(	NULL
39	NULL
)	NULL
,	NULL
and	NULL
the	NULL
authors	NULL
concluded	NULL
that	NULL
the	NULL
receptors	NULL
no	NULL
longer	NULL
contained	NULL
the	NULL
immunoreactive	NULL
portion	NULL
of	NULL
the	NULL
receptor	NULL
.	NULL

More	NULL
recently	NULL
,	NULL
Payvar	NULL
et	NULL
al	NULL
.	NULL

(	NULL
29	NULL
)	NULL
reported	NULL
that	NULL
antibodies	NULL
raised	NULL
against	NULL
the	NULL
rat	NULL
liver	NULL
glucocorticoid	NULL
receptor	NULL
did	NULL
recognize	NULL
M	NULL
,	NULL
78,000	NULL
protein	NULL
thought	NULL
to	NULL
be	NULL
a	NULL
protec-lytic	NULL
fragment	NULL
of	NULL
the	NULL
receptor	NULL
.	NULL

Since	NULL
the	NULL
antibodies	NULL
described	NULL
above	NULL
were	NULL
raised	NULL
against	NULL
DNA-cellulose-purified	NULL
receptor	NULL
,	NULL
these	NULL
results	NULL
combined	NULL
with	NULL
the	NULL
data	NULL
presented	NULL
here	NULL
raise	NULL
the	NULL
possibility	NULL
that	NULL
glucocorticoid	NULL
'receptors	NULL
purified	NULL
by	NULL
DNA-celluiose	NULL
chromatography	NULL
from	NULL
either	NULL
rat	NULL
liver	NULL
or	NULL
human	NULL
lymphoblasts	NULL
contain	NULL
a	NULL
common	NULL
immunogenic	NULL
site	NULL
.	NULL

ACKNOWLEDGMENTS	NULL
We	NULL
wish	NULL
to	NULL
thank	NULL
Jean	NULL
Bartlett	NULL
for	NULL
secretarial	NULL
assistance	NULL
in	NULL
the	NULL
preparation	NULL
of	NULL
this	NULL
manuscript	NULL
.	NULL

REFERENCES	NULL
1	NULL
.	NULL

Bloomfield	NULL
,	NULL
C.	NULL
D.	NULL
,	NULL
Smith	NULL
,	NULL
K.	NULL
A.	NULL
,	NULL
Peterson	NULL
,	NULL
B	NULL
.	NULL

A.	NULL
,	NULL
and	NULL
Munck	NULL
,	NULL
A.	NULL
Glucocorticoid	NULL
receptors	NULL
in	NULL
adult	NULL
acute	NULL
tymphoblastic	NULL
leukemia	NULL
.	NULL

Cancer	NULL
Res	NULL
.	NULL

,	NULL
41	NULL
:	NULL
4857-4860	NULL
,	NULL
1981	NULL
.	NULL

2	NULL
.	NULL

Bradford	NULL
,	NULL
M.	NULL
M.	NULL
A	NULL
rapid	NULL
and	NULL
sensitive	NULL
method	NULL
for	NULL
the	NULL
quantitation	NULL
of	NULL
microgram	NULL
quantities	NULL
of	NULL
protein	NULL
utilizing	NULL
the	NULL
principle	NULL
of	NULL
protein-dye	NULL
binding	NULL
.	NULL

Anal	NULL
.	NULL

Biochem	NULL
.	NULL

,	NULL
72	NULL
:	NULL
248-254	NULL
,	NULL
1976	NULL
.	NULL

3	NULL
.	NULL

Carlstedt-Duke	NULL
,	NULL
J.	NULL
,	NULL
Okrat	NULL
,	NULL
S.	NULL
,	NULL
Wrange	NULL
,	NULL
O.	NULL
,	NULL
and	NULL
Gustafsson	NULL
,	NULL
J.-A	NULL
.	NULL

immunochem-balanaiysisofmegucocorﬁooid	NULL
:	NULL
identification	NULL
of	NULL
a	NULL
third	NULL
domain	NULL
mmmmmmommmusmcmw	NULL
Sci	NULL
.	NULL

USA	NULL
,	NULL
79	NULL
:	NULL
4260-4264	NULL
,	NULL
1982	NULL
.	NULL

4	NULL
.	NULL

Caristedt-Duke	NULL
,	NULL
J.	NULL
,	NULL
Wmnoeo	NULL
Dahiberg	NULL
,	NULL
E.	NULL
,	NULL
Gustafsson	NULL
,	NULL
J.-A	NULL
.	NULL

,	NULL
and	NULL
Hogberg	NULL
,	NULL
B.	NULL
Tmfonnaﬁon	NULL
gucocorﬁeoidreceptahratlvacytosolbylysozo-mal	NULL
enzymes	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

,	NULL
254	NULL
:	NULL
1537-1539	NULL
,	NULL
1979	NULL
.	NULL

5.0uowsld.J.APyridoxdptmptmeirumdaltefaﬁonsh	NULL
receptor	NULL
metabolism	NULL
by	NULL
proteases	NULL
.	NULL

Biochemistry	NULL
,	NULL
19	NULL
;	NULL
6162-6170	NULL
,	NULL
1980	NULL
.	NULL

6	NULL
.	NULL

Eisen	NULL
,	NULL
H.	NULL
J	NULL
.	NULL

An	NULL
antiserum	NULL
to	NULL
the	NULL
rat	NULL
liver	NULL
glucocorticoid	NULL
receptor	NULL
.	NULL

Proc	NULL
.	NULL

Natt	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
77	NULL
:	NULL
3893-3897	NULL
,	NULL
1980	NULL
.	NULL

7	NULL
.	NULL

Elsen	NULL
,	NULL
H.	NULL
J.	NULL
,	NULL
and	NULL
Glinsmann	NULL
,	NULL
W.	NULL
H.	NULL
Maximizing	NULL
the	NULL
purification	NULL
of	NULL
the	NULL
activated	NULL
$	NULL
0008	NULL
?	NULL

!	NULL

de	NULL
receptor	NULL
by	NULL
DNA-cellulose	NULL
chromatography	NULL
.	NULL

Biochem	NULL
.	NULL

J.	NULL
,	NULL
177	NULL
:	NULL
177-183	NULL
,	NULL
197	NULL
8	NULL
.	NULL

Eisen	NULL
,	NULL
H.	NULL
J.	NULL
,	NULL
Schieenbaker	NULL
,	NULL
R.	NULL
E.	NULL
,	NULL
and	NULL
Simons	NULL
,	NULL
S.	NULL
S.	NULL
,	NULL
wAfﬂrityhbelngloe	NULL
rat	NULL
liver	NULL
glucocorticoid	NULL
receptor	NULL
:	NULL
identifica-ﬁmofcovdaﬂyhbdedreoeptorbymmwdmiedmﬁbGsJBldctmn	NULL
.	NULL

256	NULL
:	NULL
12920-12925	NULL
,	NULL
1981	NULL
.	NULL

9	NULL
.	NULL

Foster	NULL
,	NULL
C.	NULL
M.	NULL
,	NULL
Eisen	NULL
,	NULL
H.	NULL
J.	NULL
,	NULL
and	NULL
Bloomfield	NULL
,	NULL
C.	NULL
D.	NULL
Covalent	NULL
labeling	NULL
of	NULL
rat	NULL
and	NULL
human	NULL
lymphoid	NULL
glucocorticoid	NULL
receptor	NULL
.	NULL

Cancer	NULL
Res	NULL
.	NULL

,	NULL
43	NULL
:	NULL
5273-5277	NULL
,	NULL
1983	NULL
.	NULL

10	NULL
.	NULL

Gametchu	NULL
,	NULL
B.	NULL
,	NULL
and	NULL
Harrison	NULL
,	NULL
R.	NULL
W.	NULL
Characterization	NULL
of	NULL
a	NULL
monocional	NULL
tomeratlvergtmeorﬁcoidreceptor	NULL
Endocrinology	NULL
,	NULL
114	NULL
:	NULL
274-279	NULL
,	NULL
1984	NULL
.	NULL

11	NULL
.	NULL

Govindan	NULL
,	NULL
M.	NULL
V.	NULL
,	NULL
and	NULL
Sekerts	NULL
,	NULL
C.	NULL
E.	NULL
Purification	NULL
of	NULL
two	NULL
de	NULL
protehsfromrat—Iivercytosol	NULL
Eur	NULL
.	NULL

J	NULL
.	NULL

Biochem	NULL
.	NULL

,	NULL
89	NULL
:	NULL
95-104	NULL
,	NULL
1978	NULL
.	NULL

12	NULL
.	NULL

Grandics	NULL
,	NULL
P.	NULL
,	NULL
Gasser	NULL
,	NULL
D.	NULL
L	NULL
,	NULL
andLitwack	NULL
,	NULL
G.Monodonalambodestome	NULL
glucocorticoid	NULL
receptor	NULL
.	NULL

Endocrinology	NULL
,	NULL
111	NULL
:	NULL
1731-1733	NULL
,	NULL
1982	NULL
.	NULL

13	NULL
.	NULL

Greene	NULL
,	NULL
G.	NULL
L.	NULL
,	NULL
Closs	NULL
,	NULL
L.	NULL
E.	NULL
,	NULL
Fleming	NULL
,	NULL
H.	NULL
,	NULL
Desombre	NULL
,	NULL
E.	NULL
R.	NULL
,	NULL
and	NULL
Jensen	NULL
,	NULL
E.	NULL
V.	NULL
Antibodies	NULL
to	NULL
estrogen	NULL
receptor	NULL
:	NULL
immunochemical	NULL
similarity	NULL
of	NULL
estrophilin	NULL
from	NULL
various	NULL
mammalian	NULL
species	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
74	NULL
:	NULL
3681-3685	NULL
,	NULL
1977	NULL
.	NULL

14	NULL
.	NULL

Greene	NULL
,	NULL
G.	NULL
L.	NULL
,	NULL
Fitch	NULL
,	NULL
F.	NULL
W.	NULL
,	NULL
and	NULL
Jensen	NULL
,	NULL
E.	NULL
V.	NULL
Monocional	NULL
antibodies	NULL
to	NULL
estrophilin	NULL
:	NULL
probestormesmdyofestrogenreceptors	NULL
Proc	NULL
.	NULL

Nat	NULL
!	NULL

.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
77	NULL
:	NULL
157-161	NULL
,	NULL
1980	NULL
.	NULL

15	NULL
.	NULL

Harmon	NULL
,	NULL
J.	NULL
M.	NULL
,	NULL
Schmidt	NULL
,	NULL
T.	NULL
J.	NULL
,	NULL
and	NULL
Thompson	NULL
,	NULL
E.	NULL
B	NULL
.	NULL

Defective	NULL
steroid	NULL
resistant	NULL
{	NULL
301-313NewYotk.Plsmm	NULL
Corp.	NULL
,	NULL
16	NULL
.	NULL

Harmon	NULL
,	NULL
J.	NULL
M.	NULL
,	NULL
wmealmﬁonmddwmmﬂmofdexa-MummmmmmwwoamceM-m	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

,	NULL
1	NULL
:	NULL
512-521	NULL
,	NULL
1981	NULL
.	NULL

17.Ho|brookNJ	NULL
Bloomfield	NULL
,	NULL
C.	NULL
D.	NULL
,	NULL
and	NULL
Munck	NULL
,	NULL
A	NULL
.	NULL

Analysis	NULL
of	NULL
activated	NULL
and	NULL
WWMWmMWW	NULL
kemia	NULL
cells	NULL
by	NULL
rapid	NULL
DNA-disthylaminoethy	NULL
!	NULL

minicolumn	NULL
chromatography	NULL
.	NULL

Cancer	NULL
Res	NULL
.	NULL

,	NULL
43	NULL
:	NULL
4478-4482	NULL
,	NULL
1983	NULL
.	NULL

18.KesslerSWRapidisolaﬁonofaMgensﬁorncelsMﬂrastaphybcoecd	NULL
Protein	NULL
A-antibody	NULL
adsorbent	NULL
:	NULL
parameters	NULL
of	NULL
the	NULL
interaction	NULL
of	NULL
antigen	NULL
complexes	NULL
with	NULL
Protein	NULL
A.	NULL
J	NULL
.	NULL

Immunol	NULL
.	NULL

,	NULL
115	NULL
:	NULL
1617-1624	NULL
,	NULL
1975	NULL
.	NULL

4545	NULL
Downloaded	NULL
from	NULL
cancerres.aacrjournals.org	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

©	NULL
1984	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
.	NULL

J.	NULL
M.	NULL
Harmon	NULL
et	NULL
al	NULL
.	NULL

19	NULL
.	NULL

Konior	NULL
Yarbro	NULL
,	NULL
G.	NULL
S.	NULL
,	NULL
Lippman	NULL
,	NULL
M.	NULL
E.	NULL
,	NULL
Johnson	NULL
,	NULL
G.	NULL
E.	NULL
,	NULL
and	NULL
Leventhal	NULL
,	NULL
B.	NULL
G.	NULL
FEBS	NULL
Lett	NULL
.	NULL

,	NULL
121	NULL
;	NULL
249-252	NULL
,	NULL
1980	NULL
.	NULL

Glucocorticoid	NULL
receptors	NULL
in	NULL
subpopulations	NULL
of	NULL
childhood	NULL
acute	NULL
lymphocytic	NULL
33.Sd1midtTJ	NULL
Harmon	NULL
,	NULL
J.	NULL
M.	NULL
,	NULL
and	NULL
Thompson	NULL
,	NULL
E.	NULL
B	NULL
.	NULL

``	NULL
Activation-labile	NULL
``	NULL
gluco-leukemia	NULL
.	NULL

Cancer	NULL
Res	NULL
.	NULL

,	NULL
37	NULL
:	NULL
2688-2695	NULL
,	NULL
1977.	NULL
corticoid-receptor	NULL
complexes	NULL
of	NULL
a	NULL
steroid-resistant	NULL
variant	NULL
of	NULL
CEM-C7	NULL
human	NULL
20	NULL
.	NULL

Laemmli	NULL
,	NULL
U.	NULL
K.	NULL
Cleavage	NULL
of	NULL
structural	NULL
proteins	NULL
during	NULL
assembly	NULL
of	NULL
the	NULL
head	NULL
of	NULL
lymphoid	NULL
cells	NULL
.	NULL

Nature	NULL
(	NULL
Lond	NULL
.	NULL
)	NULL

,	NULL
286	NULL
:	NULL
507-510	NULL
,	NULL
1980.	NULL
bacteriophage	NULL
T	NULL
,	NULL
.	NULL

Nature	NULL
(	NULL
Lond	NULL
.	NULL
)	NULL

,	NULL
227	NULL
:	NULL
680-685	NULL
,	NULL
1970	NULL
.	NULL

34	NULL
.	NULL

Schmidt	NULL
,	NULL
T.	NULL
J.	NULL
,	NULL
and	NULL
Thompson	NULL
,	NULL
E.	NULL
B.	NULL
Glucocorticoid	NULL
receptors	NULL
and	NULL
21	NULL
.	NULL

Lippman	NULL
,	NULL
M.	NULL
E.	NULL
,	NULL
Yarbro	NULL
,	NULL
G.	NULL
K.	NULL
,	NULL
and	NULL
Leventhal	NULL
,	NULL
B.	NULL
G.	NULL
Clinical	NULL
implications	NULL
of	NULL
synthetase	NULL
in	NULL
leukemic	NULL
Sézary	NULL
cells	NULL
.	NULL

Cancer	NULL
Res	NULL
.	NULL

,	NULL
39	NULL
:	NULL
376-382	NULL
,	NULL
1979.	NULL
glucocorticoid	NULL
receptors	NULL
in	NULL
human	NULL
leukemia	NULL
.	NULL

Cancer	NULL
Res	NULL
.	NULL

,	NULL
38	NULL
:	NULL
4251-4256	NULL
,	NULL
-	NULL
35	NULL
.	NULL

Sherman	NULL
,	NULL
M.	NULL
R.	NULL
,	NULL
Pickering	NULL
,	NULL
L.	NULL
A.	NULL
,	NULL
Rollwagen	NULL
,	NULL
F.	NULL
M.	NULL
,	NULL
and	NULL
Miler	NULL
,	NULL
L.	NULL
K.	NULL
Mero-1978	NULL
.	NULL

receptorsprotedyucﬁagmemsofreoeptusoonwumunsmerddm	NULL
22	NULL
.	NULL

Logeat	NULL
,	NULL
F.	NULL
,	NULL
Hai	NULL
,	NULL
M.	NULL
T.	NULL
V.	NULL
,	NULL
and	NULL
Milgrom	NULL
,	NULL
E.	NULL
Antibodies	NULL
to	NULL
rabbit	NULL
progesterone	NULL
site	NULL
.	NULL

Fed	NULL
.	NULL

Proc	NULL
.	NULL

,	NULL
37	NULL
:	NULL
167-173	NULL
,	NULL
1976.	NULL
receptor	NULL
:	NULL
cross-reaction	NULL
with	NULL
human	NULL
receptor	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
78	NULL
:	NULL
-	NULL
36	NULL
.	NULL

Sherman	NULL
,	NULL
M.	NULL
R.	NULL
,	NULL
Tuazon	NULL
,	NULL
F.	NULL
B.	NULL
,	NULL
and	NULL
S6mijen	NULL
,	NULL
G.	NULL
J	NULL
.	NULL

Stabilization	NULL
and	NULL
cleavage	NULL
1426-1430	NULL
,	NULL
1981.	NULL
ofsteroidreoeptorswﬁectsofbupepﬁnmdmoiybdatemmkldwygwo-	NULL
23	NULL
.	NULL

Martin	NULL
,	NULL
R.	NULL
G.	NULL
,	NULL
and	NULL
Ames	NULL
,	NULL
B.	NULL
N.	NULL
A	NULL
method	NULL
for	NULL
determining	NULL
the	NULL
sedimentation	NULL
corticoid	NULL
receptors	NULL
.	NULL

in	NULL
:	NULL
R.	NULL
J.	NULL
Soto	NULL
,	NULL
A.	NULL
DeNicola	NULL
,	NULL
and	NULL
J.	NULL
Blaquier	NULL
(	NULL
eds	NULL
.	NULL
)	NULL

,	NULL
Patho-behavior	NULL
of	NULL
enzymes	NULL
:	NULL
application	NULL
to	NULL
protein	NULL
mixtures	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

,	NULL
236	NULL
:	NULL
physiology	NULL
of	NULL
Endocrine	NULL
Diseases	NULL
and	NULL
Mechanisms	NULL
of	NULL
Hormone	NULL
Action	NULL
,	NULL
pp	NULL
.	NULL

1372-1379	NULL
,	NULL
1961	NULL
.	NULL

321-337	NULL
,	NULL
New	NULL
York	NULL
:	NULL
Alan	NULL
R.	NULL
Liss	NULL
,	NULL
Inc.	NULL
,	NULL
1981	NULL
.	NULL

24	NULL
.	NULL

Mastrangelo	NULL
,	NULL
R.	NULL
,	NULL
Malandrino	NULL
,	NULL
R.	NULL
,	NULL
Riccardi	NULL
,	NULL
R.	NULL
,	NULL
Longo	NULL
,	NULL
P.	NULL
,	NULL
Ranelletti	NULL
,	NULL
F.	NULL
O.	NULL
,	NULL
and	NULL
_	NULL
37	NULL
.	NULL

Simons	NULL
,	NULL
S.	NULL
S.	NULL
,	NULL
Jr.	NULL
,	NULL
Pons	NULL
,	NULL
M.	NULL
,	NULL
andJohnson	NULL
D.	NULL
F.	NULL
«	NULL
-Keto	NULL
mesylate	NULL
:	NULL
a	NULL
reactive	NULL
,	NULL
lacobelli	NULL
,	NULL
S.	NULL
Clinical	NULL
implications	NULL
of	NULL
glucocorticoid	NULL
receptor	NULL
studies	NULL
in	NULL
childhood	NULL
Mspeaﬁcﬁmchonalgroup	NULL
J.	NULL
Org	NULL
.	NULL

Chem	NULL
.	NULL

,	NULL
45	NULL
:	NULL
3084-3088	NULL
,	NULL
1980.	NULL
acute	NULL
lymphoblastic	NULL
leukemia	NULL
.	NULL

Blood	NULL
,	NULL
56	NULL
:	NULL
1036-1040	NULL
,	NULL
1980	NULL
.	NULL

38	NULL
.	NULL

Simons	NULL
,	NULL
S.	NULL
S.	NULL
,	NULL
Jr.	NULL
,	NULL
Schieenbaker	NULL
,	NULL
R.	NULL
E.	NULL
,	NULL
andEisenHJActivaﬁmofcovuent	NULL
25	NULL
.	NULL

McCaffrey	NULL
,	NULL
R.	NULL
,	NULL
Lillquist	NULL
,	NULL
A.	NULL
,	NULL
and	NULL
Bell	NULL
,	NULL
R.	NULL
Abnormal	NULL
glucocorticoid	NULL
receptors	NULL
in	NULL
affinity	NULL
laudedgluoocorﬁooid	NULL
receptor-steroid	NULL
complexes	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

,	NULL
258	NULL
:	NULL
acute	NULL
leukemia	NULL
cells	NULL
.	NULL

Blood	NULL
,	NULL
59	NULL
:	NULL
393-400	NULL
,	NULL
1982	NULL
.	NULL

2229-2238	NULL
,	NULL
1983	NULL
.	NULL

26	NULL
.	NULL

Nordeen	NULL
,	NULL
S.	NULL
K.	NULL
,	NULL
Lan	NULL
,	NULL
N.	NULL
C.	NULL
,	NULL
Showers	NULL
,	NULL
M.	NULL
O.	NULL
,	NULL
and	NULL
Baxter	NULL
,	NULL
J.	NULL
D.	NULL
Photoaffinity	NULL
_	NULL
39	NULL
.	NULL

Simons	NULL
,	NULL
S.	NULL
S.	NULL
,	NULL
Jr.	NULL
,	NULL
and	NULL
Thompson	NULL
,	NULL
E.	NULL
B.	NULL
Dexamethasone	NULL
21-mesylate	NULL
:	NULL
an	NULL
labehgofghmcamo'dreoeptorsJBbIChem	NULL
256	NULL
:	NULL
10503-10508	NULL
,	NULL
1981.	NULL
affinity	NULL
label	NULL
of	NULL
glucocorticoid	NULL
receptors	NULL
from	NULL
hepatoma	NULL
tissue	NULL
culture	NULL
cells	NULL
.	NULL

27	NULL
.	NULL

Okret	NULL
,	NULL
S.	NULL
,	NULL
Caristedt-Duke	NULL
,	NULL
J.	NULL
,	NULL
Wrange	NULL
,	NULL
O.	NULL
,	NULL
Caristrom	NULL
,	NULL
K.	NULL
,	NULL
and	NULL
Gustafsson	NULL
,	NULL
J.-	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
78	NULL
:	NULL
3541-3545	NULL
,	NULL
1981	NULL
.	NULL

A	NULL
.	NULL

Characterization	NULL
of	NULL
an	NULL
antiserum	NULL
against	NULL
the	NULL
glucocorticoid	NULL
receptor	NULL
.	NULL

-	NULL
40	NULL
.	NULL

Stevens	NULL
,	NULL
J.	NULL
,	NULL
Eisen	NULL
,	NULL
H.	NULL
J.	NULL
,	NULL
Stevens	NULL
,	NULL
Y.-W.	NULL
,	NULL
Haubenstock	NULL
,	NULL
H.	NULL
,	NULL
Rosenthal	NULL
,	NULL
R.	NULL
L.	NULL
,	NULL
Biochim	NULL
.	NULL

Biophys	NULL
.	NULL

Acta	NULL
,	NULL
677	NULL
:	NULL
205-219	NULL
,	NULL
1981.	NULL
and	NULL
Artishevsky	NULL
,	NULL
A.	NULL
Immunochemical	NULL
differences	NULL
between	NULL
glucocorticoid	NULL
re	NULL
28	NULL
.	NULL

Okret	NULL
,	NULL
S.	NULL
,	NULL
Stevens	NULL
,	NULL
Y.-W.	NULL
,	NULL
Carlstedt-Duke	NULL
,	NULL
J.	NULL
,	NULL
Wrange	NULL
,	NULL
O.	NULL
,	NULL
Gustafsson	NULL
,	NULL
J.-A	NULL
.	NULL

,	NULL
ceptors	NULL
from	NULL
corticoid-sensitive	NULL
and	NULL
-resistant	NULL
malignant	NULL
lymphocytes	NULL
.	NULL

Cancer	NULL
andStevens	NULL
J.	NULL
Absenoehguooeotﬁcotd-resustantmxselymptunaPﬂsa	NULL
Res	NULL
.	NULL

,	NULL
41	NULL
:	NULL
134-137	NULL
,	NULL
1981.	NULL
of	NULL
a	NULL
glucocorticoid	NULL
receptor	NULL
domain	NULL
responsible	NULL
for	NULL
biological	NULL
effects	NULL
.	NULL

Cancer	NULL
_	NULL
41	NULL
.	NULL

Stevens	NULL
,	NULL
J.	NULL
,	NULL
and	NULL
Stevens	NULL
,	NULL
Y.-W	NULL
.	NULL

Influence	NULL
of	NULL
limited	NULL
proteolysis	NULL
on	NULL
the	NULL
physi-Res	NULL
.	NULL

,	NULL
43	NULL
:	NULL
3127-3131	NULL
,	NULL
1983.	NULL
ochemical	NULL
and	NULL
DNA-binding	NULL
properties	NULL
of	NULL
glucocorticoid	NULL
receptors	NULL
from	NULL
corti-	NULL
29	NULL
.	NULL

Payvar	NULL
.	NULL

F.	NULL
,	NULL
DeFranco	NULL
,	NULL
D.	NULL
,	NULL
Firestone	NULL
,	NULL
G.	NULL
L.	NULL
,	NULL
Edgar	NULL
,	NULL
B.	NULL
,	NULL
Wrange	NULL
,	NULL
O.	NULL
,	NULL
Okret	NULL
,	NULL
S.	NULL
,	NULL
coid-sensitive	NULL
and	NULL
resistant	NULL
mouse	NULL
lymphoma	NULL
P1798	NULL
.	NULL

Cancer	NULL
Res	NULL
.	NULL

,	NULL
41	NULL
:	NULL
125-Gustafsson	NULL
,	NULL
J.-A	NULL
.	NULL

,	NULL
and	NULL
Yamamoto	NULL
,	NULL
K.	NULL
R.	NULL
Sequence-specific	NULL
binding	NULL
of	NULL
gluco-	NULL
133	NULL
,	NULL
1981.	NULL
corticold	NULL
receptor	NULL
to	NULL
MTV	NULL
DNA	NULL
at	NULL
sites	NULL
within	NULL
and	NULL
upstream	NULL
of	NULL
the	NULL
transcribed	NULL
_	NULL
42	NULL
.	NULL

Vedeckis	NULL
,	NULL
W.	NULL
V.	NULL
Limited	NULL
proteolysis	NULL
of	NULL
the	NULL
mouse	NULL
liver	NULL
glucocorticoid	NULL
receptor	NULL
.	NULL

region	NULL
.	NULL

Cell	NULL
,	NULL
35	NULL
:	NULL
381-392	NULL
,	NULL
1983	NULL
.	NULL

Biochemistry	NULL
,	NULL
22	NULL
:	NULL
1975-1983	NULL
,	NULL
1983	NULL
.	NULL

30	NULL
.	NULL

Pike	NULL
,	NULL
J.	NULL
W.	NULL
,	NULL
Donaldson	NULL
,	NULL
C.	NULL
A.	NULL
,	NULL
Marion	NULL
,	NULL
S.	NULL
L.	NULL
,	NULL
and	NULL
Haussler	NULL
,	NULL
M.	NULL
R.	NULL
Development	NULL
_	NULL
43	NULL
.	NULL

Westphal	NULL
,	NULL
H.	NULL
M.	NULL
,	NULL
Moldenhaver	NULL
,	NULL
G.	NULL
,	NULL
and	NULL
Beato	NULL
,	NULL
M.	NULL
Monoclonal	NULL
antibodies	NULL
to	NULL
of	NULL
hybridomas	NULL
secreting	NULL
monoclonal	NULL
antibodies	NULL
to	NULL
the	NULL
chicken	NULL
intestinal	NULL
14,25-	NULL
the	NULL
rat	NULL
liver	NULL
gkmcmieoid	NULL
receptor	NULL
.	NULL

EMBO	NULL
J.	NULL
,	NULL
1	NULL
:	NULL
1467-1471	NULL
,	NULL
1982.	NULL
dihydroxyvitamin	NULL
Ds	NULL
receptor	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
79	NULL
;	NULL
7719-7723	NULL
,	NULL
-	NULL
44	NULL
.	NULL

Wheeler	NULL
,	NULL
R.	NULL
H.	NULL
,	NULL
Leach	NULL
,	NULL
K.	NULL
L.	NULL
,	NULL
LaForest	NULL
,	NULL
A.	NULL
C.	NULL
,	NULL
O'Toole	NULL
,	NULL
T.	NULL
E.	NULL
,	NULL
Wagner	NULL
,	NULL
R.	NULL
,	NULL
and	NULL
1982	NULL
.	NULL

Pratt	NULL
,	NULL
W.	NULL
B.	NULL
Glucocorticoid	NULL
receptor	NULL
activation	NULL
and	NULL
inactivation	NULL
in	NULL
cultured	NULL
31	NULL
.	NULL

Renoir	NULL
,	NULL
J.-M.	NULL
,	NULL
Radanyi	NULL
,	NULL
C.	NULL
,	NULL
Yang	NULL
,	NULL
C.-R.	NULL
,	NULL
and	NULL
Baulieu	NULL
,	NULL
E.-E.	NULL
Antibodies	NULL
against	NULL
human	NULL
lymphocytes	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

,	NULL
256	NULL
:	NULL
434-441	NULL
,	NULL
1981.	NULL
progesterone	NULL
receptor	NULL
from	NULL
chick	NULL
oviduct	NULL
.	NULL

Eur	NULL
.	NULL

J	NULL
.	NULL

Biochem	NULL
.	NULL

,	NULL
127	NULL
:	NULL
81-86	NULL
,	NULL
1982	NULL
.	NULL

-	NULL
45	NULL
.	NULL

Wrange	NULL
,	NULL
O.	NULL
,	NULL
Caristedt-Duke	NULL
,	NULL
J.	NULL
,	NULL
and	NULL
Gustafsson	NULL
,	NULL
J.-A	NULL
.	NULL

Purification	NULL
of	NULL
the	NULL
32	NULL
.	NULL

Rousseau	NULL
,	NULL
G.	NULL
G.	NULL
,	NULL
Cambron	NULL
,	NULL
P.	NULL
,	NULL
and	NULL
Amar-Costesec	NULL
,	NULL
A.	NULL
Glucocorticoid	NULL
receptor	NULL
glucocorticoid	NULL
receptor	NULL
from	NULL
rat	NULL
liver	NULL
cytosol	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

,	NULL
254	NULL
:	NULL
9284-9290	NULL
,	NULL
mediated	NULL
stimulation	NULL
of	NULL
5'-nucieotidase	NULL
in	NULL
human	NULL
lymphoblastoid	NULL
IM-9	NULL
cells	NULL
.	NULL

1979	NULL
.	NULL

Fig	NULL
.	NULL

1	NULL
.	NULL

ImmoadsorpﬁmofﬁﬂlDM-IabeledlM-leueocomooidreceptorsAmnecywsdlabeledwm200nMFHJDMinmeabseme	NULL
(	NULL
Lane1	NULL
)	NULL
orprewvoe	NULL
(	NULL
Lene	NULL
2	NULL
)	NULL
of10puuﬂabeledTAwassubjectedtoSDS-PAGEasdescﬂbedh'MetenalsandMethods	NULL
The	NULL
4	NULL
TA-competable	NULL
bands	NULL
and	NULL
their	NULL
approximate	NULL
molecular	NULL
weights	NULL
are	NULL
indicated	NULL
by	NULL
the	NULL
arrows	NULL
to	NULL
the	NULL
left	NULL
of	NULL
the	NULL
figure	NULL
.	NULL

In	NULL
B	NULL
,	NULL
cytosol	NULL
was	NULL
labeled	NULL
with	NULL
200	NULL
nm	NULL
[	NULL
°HJDM	NULL
as	NULL
above	NULL
.	NULL

Samples	NULL
labeled	NULL
with	NULL
[	NULL
°HJDM	NULL
were	NULL
submitted	NULL
to	NULL
SDS-PAGE	NULL
either	NULL
directly	NULL
(	NULL
Lane	NULL
1	NULL
)	NULL
or	NULL
after	NULL
immunoadsorption	NULL
with	NULL
immune	NULL
(	NULL
Lane	NULL
2	NULL
)	NULL
or	NULL
preimmune	NULL
(	NULL
Lane	NULL
3	NULL
)	NULL
serum	NULL
.	NULL

Lane	NULL
1	NULL
was	NULL
intentionally	NULL
overloaded	NULL
to	NULL
indicate	NULL
the	NULL
many	NULL
proteins	NULL
labeled	NULL
by	NULL
[	NULL
°HJDM	NULL
.	NULL

phos	NULL
b	NULL
,	NULL
phosphorylase	NULL
b	NULL
;	NULL
BSA	NULL
,	NULL
bovine	NULL
serum	NULL
albumin	NULL
;	NULL
OVA	NULL
,	NULL
ovalbumin	NULL
.	NULL

Fig	NULL
.	NULL

2.	NULL
lmxnadsorpﬁonofﬁpMﬁbeledCEMgkmwﬁeoudreceptas	NULL
In	NULL
A	NULL
,	NULL
CEM-C7	NULL
cytosol	NULL
was	NULL
labeled	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
200	NULL
nm	NULL
{	NULL
°HJDM	NULL
for	NULL
4	NULL
hr	NULL
in	NULL
the	NULL
absence	NULL
(	NULL
Lane	NULL
1	NULL
)	NULL
or	NULL
presence	NULL
(	NULL
Lane	NULL
2	NULL
)	NULL
of	NULL
10	NULL
«	NULL
M	NULL
unlabeled	NULL
TA	NULL
.	NULL

Samples	NULL
were	NULL
subjected	NULL
to	NULL
electrophoresis	NULL
in	NULL
8	NULL
%	NULL
SDS-polyacrylamide	NULL
gels	NULL
as	NULL
described	NULL
in	NULL
``	NULL
Materials	NULL
and	NULL
Methods	NULL
.	NULL
``	NULL

In	NULL
B	NULL
,	NULL
CEM-C7	NULL
cytosol	NULL
was	NULL
labeled	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
200	NULL
nu	NULL
[	NULL
°HJDM	NULL
for	NULL
4	NULL
hr	NULL
at	NULL
0-4°	NULL
in	NULL
the	NULL
absence	NULL
(	NULL
Lanes	NULL
1	NULL
and	NULL
2	NULL
)	NULL
or	NULL
presence	NULL
(	NULL
Lane	NULL
3	NULL
)	NULL
of	NULL
10	NULL
um	NULL
unlabeled	NULL
TA	NULL
.	NULL

After	NULL
affinity	NULL
labeling	NULL
,	NULL
20	NULL
«	NULL
I	NULL
of	NULL
immune	NULL
(	NULL
Lanes	NULL
1	NULL
and	NULL
3	NULL
)	NULL
or	NULL
nonimmune	NULL
(	NULL
Lane	NULL
2	NULL
)	NULL
serum	NULL
were	NULL
added	NULL
to	NULL
250	NULL
«	NULL
!	NULL

of	NULL
labeled	NULL
cytosol	NULL
,	NULL
and	NULL
immune	NULL
complexes	NULL
were	NULL
isolated	NULL
as	NULL
described	NULL
in	NULL
``	NULL
Materials	NULL
and	NULL
Methods	NULL
.	NULL
``	NULL

in	NULL
C	NULL
,	NULL
cytosol	NULL
prepared	NULL
from	NULL
ICR-27	NULL
was	NULL
treated	NULL
in	NULL
an	NULL
identical	NULL
fashion	NULL
as	NULL
that	NULL
of	NULL
CEM-C7	NULL
presented	NULL
in	NULL
B	NULL
.	NULL

The	NULL
mobility	NULL
of	NULL
the	NULL
**C-marker	NULL
proteins	NULL
myosin	NULL
(	NULL
M	NULL
)	NULL
,	NULL
phosphorylase	NULL
b	NULL
(	NULL
P	NULL
)	NULL
,	NULL
bovine	NULL
serum	NULL
albumin	NULL
(	NULL
B	NULL
)	NULL
,	NULL
ovalbumin	NULL
(	NULL
0	NULL
)	NULL
,	NULL
and	NULL
carbonic	NULL
anhydrase	NULL
(	NULL
C	NULL
)	NULL
is	NULL
indicated	NULL
.	NULL

4546	NULL
CANCER	NULL
RESEARCH	NULL
VOL	NULL
.	NULL

44	NULL
Downloaded	NULL
from	NULL
cancerres.aacrjournals.org	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

©	NULL
1984	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
.	NULL

Anti-Human	NULL
Glucocorticoid	NULL
Receptor	NULL
Antibodies	NULL
A	NULL
B	NULL
1	NULL
2	NULL
1	NULL
3	NULL
--	NULL
myosin	NULL
90K	NULL
mean	NULL
«	NULL
<	NULL
-	NULL
phos	NULL
b	NULL
18K-*	NULL
<	NULL
-	NULL
BSA	NULL
1K-	NULL
»	NULL
-~	NULL
«	NULL
-	NULL
DVA	NULL
38.5K	NULL
-	NULL
»	NULL
1	NULL
A	NULL
B	NULL
C	NULL
1	NULL
.	NULL

2	NULL
1:2	NULL
3	NULL
1	NULL
2°	NULL
3	NULL
<	NULL
--	NULL
-	NULL
M	NULL
|	NULL
i~	NULL
--	NULL
-P	NULL
90K	NULL
--	NULL
-	NULL
»	NULL
<	NULL
ag	NULL
»	NULL
*	NULL
me	NULL
<	NULL
in	NULL
Ep	NULL
#	NULL
-	NULL
«	NULL
lp	NULL
OCTOBER	NULL
1984	NULL
4547	NULL
Downloaded	NULL
from	NULL
cancerres.aacrjournals.org	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

©	NULL
1984	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
.	NULL

AAGR	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
Cancer	NULL
Research	NULL
The	NULL
Journal	NULL
of	NULL
Cancer	NULL
Research	NULL
(	NULL
1916-1930	NULL
)	NULL
|	NULL
The	NULL
American	NULL
Journal	NULL
of	NULL
Cancer	NULL
(	NULL
1931-1940	NULL
)	NULL
Identification	NULL
of	NULL
Human	NULL
Leukemic	NULL
Glucocorticoid	NULL
Receptors	NULL
Using	NULL
Affinity	NULL
Labeling	NULL
and	NULL
Anti-Human	NULL
Glucocorticoid	NULL
Receptor	NULL
Antibodies	NULL
Jeffrey	NULL
M.	NULL
Harmon	NULL
,	NULL
Howard	NULL
J.	NULL
Eisen	NULL
,	NULL
Steven	NULL
T.	NULL
Brower	NULL
,	NULL
et	NULL
al	NULL
.	NULL

Cancer	NULL
Res	NULL
1984	NULL
;	NULL
44:4540-4547	NULL
.	NULL

Updated	NULL
version	NULL
Access	NULL
the	NULL
most	NULL
recent	NULL
version	NULL
of	NULL
this	NULL
article	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//cancerres.aacrjournals.org/content/44/10/4540	NULL
E-mail	NULL
alerts	NULL
Reprints	NULL
and	NULL
Subscriptions	NULL
Permissions	NULL
Sign	NULL
up	NULL
to	NULL
receive	NULL
free	NULL
email-alerts	NULL
related	NULL
to	NULL
this	NULL
article	NULL
or	NULL
journal	NULL
.	NULL

To	NULL
order	NULL
reprints	NULL
of	NULL
this	NULL
article	NULL
or	NULL
to	NULL
subscribe	NULL
to	NULL
the	NULL
journal	NULL
,	NULL
contact	NULL
the	NULL
AACR	NULL
Publications	NULL
Department	NULL
at	NULL
pubs	NULL
@	NULL
aacr.org	NULL
.	NULL

To	NULL
request	NULL
permission	NULL
to	NULL
re-use	NULL
all	NULL
or	NULL
part	NULL
of	NULL
this	NULL
article	NULL
,	NULL
use	NULL
this	NULL
link	NULL
http	NULL
:	NULL
//cancerres.aacrjournals.org/content/44/10/4540	NULL
.	NULL

Click	NULL
on	NULL
``	NULL
Request	NULL
Permissions	NULL
``	NULL
which	NULL
will	NULL
take	NULL
you	NULL
to	NULL
the	NULL
Copyright	NULL
Clearance	NULL
Center	NULL
's	NULL
(	NULL
CCC	NULL
)	NULL
Rightslink	NULL
site	NULL
.	NULL

Downloaded	NULL
from	NULL
cancerres.aacrjournals.org	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

©	NULL
1984	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
.	NULL

